Global HC Analytics LLC ~ New Jersey's Premier Healthcare and Clean Engineering Consultancy...
Now a Book Publisher, Too!!!
The Future of HealthCare Analytics is Right Here at https://www.theghca.com
Our Founder & Managing Principal, Jeff Conroy, has Self-Published our first Book, "Blood Money", his exclusive autobiographical memoirs of his "Celgene Decade".
You can email us at globalhcanalytics@gmail.com for a PDF or search "Celgene Memoirs" on Amazon Prime for the Paperback.
The First Chapter is available here as well on Jeff's LinkedIn Profile:
God Bless America...Again. (GBA...A)
Free Classic Country Here, Too: https://www.youtube.com/watch?v=MTGKA77WVUk
Make America Green... Again! (MAGA!)
Get America Going... Alright? (GAGA?)
Version Shared on www.theghca.com
October 27th, 2026 ~ 11:15AM EST (North Jersey Time)
Prologue (Chapter 1) The Multiple Myeloma Monster in the Former Summit Middle School
There is a strange, jarring poetry to saving cancer patients inside a building that once taught middle school Gymnastics, Grammar, and Algebra.
Celgene’s global headquarters in Summit, New Jersey, was an uncanny metaphor for the company itself. It didn’t look like a $100 billion biopharma titan or the polished Manhattan financial institution it would eventually resemble. It was a converted middle school—an odd, repurposed campus housing one of the most profitable oncology engines in the history of biotechnology.
Walking through the complex in August 2011, and for years after, you could still feel the phantom geometry of institutional hallways and repurposed classrooms. Yet behind those brick walls sat a commercial machine built on pills—specifically, immunomodulatory drugs derived from thalidomide. Revlimid, the crown jewel, was printing money at an unheard‑of scale. Multiple myeloma accounted for roughly 90 percent of company sales, with myelodysplastic syndromes (MDS) adding a modest tail. Pomalyst was on deck, primed to generate billions more.
Celgene was a financial monster. But it was a single‑organism monster, and Revlimid’s patent cliff was already visible on the horizon.
Attempts to expand immunomodulatory drugs into solid tumors hit a hard biological wall. Solid tumors—lung, breast, pancreatic—were an entirely different beast. To satisfy Wall Street’s insatiable demand for growth, Celgene did what it did best: it wrote a massive check. In June 2010, the company acquired Abraxis BioScience for $2.9 billion to obtain Abraxane, a nanoparticle albumin‑bound paclitaxel designed for solid tumors. The main reason to buy Abraxis was because of Abraxane's potential to help metastatic pancreatic cancer patients and also potentially triple negative breast cancer (TNBC). While Abraxane ultimately had a positive phase 3 readout in metastatic pancreatic cancer (a 2-month overall survival benefit in PDAC which led to it becoming a $1B drug, along with creative contracting structures and a strong education, AKA pharmaceutical marketing, campaign), it did not succeed in TNBC. But the learnings from how Abraxis was developed and then turned into a blockbuster are important now as Revolution Medicines, Immuneering Corporation, and the amazing Pancreatic Cancer Action Network—amongst others—work to further improve Overall Survival (OS) and Quality of Life (QoL) for these pancreatic cancer patients.
The acquisition sent a signal to the rest of the world's biopharma. Celgene had won a big, competitive bid for a compelling asset. But while the executive suite celebrated, commercial leadership hit an immediate operational crisis: the entire biostatistical and reporting infrastructure had been built too simply. True Hematology-Oncology and Solid Tumor commercialization required completely different data models, tracking frameworks, and real‑world intelligence engines. Legacy analysts—accustomed to pushing canned quarterly spreadsheets—were simply out of their depth. And as internal trials failed in solid tumors, Abraxane became the lone blockbuster candidate once metastatic pancreatic cancer data read out and won FDA approval—an extraordinary opportunity to combat one of humanity’s deadliest malignancies.
Celgene didn’t need another traditional pharma market researcher. It needed a Computer, or Systems, Engineer who could build a commercial warfare engine from scratch. CEO Bob "Huggy Bear" Hugin had instituted an uncompromising mandate: reduce reliance on remote contractors, no outsourced agencies. Bodies in seats, in Summit, working together and learning together. Every. Single. Day. I prefer the Hybrid model... but I learned so much by being In Person, and I hope my LinkedIn audience agrees that In Meeting Work is Important.
For nearly a year, the search dragged on. The candidate pool of database architects who understood complex systems code, lived within commuting distance of Summit (the Hilltopper city of New Jersey), and possessed real‑world operational drive was virtually nonexistent.
Until August 2011, when I walked through the doors and people had no idea who I was or what I was doing for my team and the entire US Commercial Organization. Even Shawn Tomasello asked me in late 2012—over a year after I joined!—what I did at a Sales Training Lunch. I calmly explained that I worked for Max in Sales Operations, whom she liked, and that I was a Senior Analyst working to support the entire sales and marketing team with best-in-class analytics. I also mentioned that I heard she was from Ohio—which I also was. Shawn was amazing. She was tough, but led like a Celgene executive should. She left in 2014 and hit several home runs in a row—she is still a Legend to those who followed her moves and invested in companies just because she joined, e.g., Pharmacyclics, an AbbVie Company (before it was bought by ABBV) and Kite Pharma (again... before it was bought by Gilead Sciences!). There were many Legends of Celgene like Shawn who moved on to prosperity. I learned a lot from Shawn and seeing her work—I hope she knows how much I still admire her grit, success, and Blue Collar Ohio Mentality when it comes to Work, Mentorship, and Phamily (Pharma Family).
My path to Summit was forged far from New Jersey pharma. After graduating from Northwestern University a few years before with an Honors GPA in Computer Engineering—essentially a degree in systems engineering based on how I approached school (as a job) —I cut my teeth working in Chicago Consulting as a data migration / early-AI expert for Premier International. I understood database logic, data architecture, and technical execution down to the metal. From 2009 to 2011, I applied those skills to the federal defense sector while working under a Secret Security Clearance. It was high‑stakes analytical, but the Bureaucracy was Stifling. I wanted an industry that moved with speed, where engineering precision had immediate human impact. Healthcare was the natural progression.
I relocated to New Jersey in March 2010, spending just over a year in general biopharma operations consulting out of Princeton. The work was demanding, the hours long, and the exposure to early immunotherapy platforms convinced me that a massive wave of cancer treatment was on the horizon. I knew I had to work for a cancer firm.
When the recruiter - Shawn O'Rourke ~ some Yale graduate from Colorado ~ called in June 2011, I knew I had to take the leap. Celgene was growing desperate; their analytical insights were stalling because nobody could construct the analytical architecture required for hematology, their blood cancer portfolio which Marketing and Leadership had too many questions to answer. .
When I informed my consulting firm that I was leaving, they panicked. They offered a corporate golden ticket: stay, and they would
guarantee my spot at a top‑tier business school—a $300,000 MBA path. Simultaneously, a larger pharma client tried to recruit me for a higher‑ranking Manager role. I turned both down. I preferred Celgene’s sharp focus on high‑unmet‑need malignancies, and I respected the team at Summit. I chose raw hustle, equity options, and the pressure cooker. I really like Max Kosoy, my first Biophamily Boss, his boss Kevin Sweeney, and all I interviewed with: Mary "My First Big Sister at Sell-gene" Kiefer, Stephen "The Sleeve" Greeley, and Virginia "Mom Boss" Krause.
In August 2011, I officially joined Celgene Corporation in Summit and then reported to the 300 Connell Building in Berkeley Heihts as a Senior Analyst of Sales Operations - Marketing Support. It was a life‑changing pivot—one that placed me directly inside the engine for the most lucrative, reckless, and catastrophic decade in biopharma history.
When I arrived, Celgene was undergoing a fundamental shift in corporate identity. The foundation had been shaped by co‑founder Sol Barer, a brilliant scientist who ran the company like an academic lab that had struck oil. Under Sol, the dogma was that “the clinical data spoke for itself.” Unfortunately Sol was wrong and the stock had flatlined.
Sol was stepping back as the company outgrew its scientific origins, and Bob Hugin was taking control as the New CEO. Joining in 1999 as a former Marine officer with a Princeton University undergraduate degree and a Darden MBA, Hugin brought Wall Street discipline to Summit. Clinical data and Financially Growth should no longer simply “speak”—it had to be weaponized for strategic execution, field force alignment, and market dominance. Hugin was a disciplined strategist who knew how to raise billions, maintain capital metrics, and lead a Spartan, Wall Street-like operational culture.
I stepped into the building just as Bob Hugin took over. My mandate: take ownership of Celgene’s data architecture, integrate all tumors into a true commercial engine, and redesign the analytics powering Celgene’s growth.
Over the coming years, I became the primary architect of those analytical systems for US Commercial at Celgene which drove the majority of the company’s revenues—the de facto data and AI lead long before the term became corporate currency. Yet as my scope grew, I turned down offers to transition into Business Development Analytics three separate times. Watching the deal desk operate, I saw that without financial disciplinarian Jackie Fouse steering capital allocation, BD was becoming addicted to high‑risk option‑hoarding rather than balance‑sheet rigor.
From the outside, Celgene looked unstoppable. From the inside, early operational friction was evident. The legacy IT infrastructure was severely outdated. Standard data‑science tools like SAS, Python Coding, and Tableau were restricted or inaccessible until many years later. To deliver, I engineered custom solutions in legacy Microsoft Access using VBA and raw SQL —workarounds that saved millions in external consulting fees and rapidly elevated my standing within commercial operations. We were dragging the company into the modern computing era through sheer engineering force. We designed solutions From the Field, By the Field, and For the Field, as my dear friends Mary Kiefer, Bill Spruill , Eddie Dowling , and of course David Wedlake and Mouzetta Zumwalt-Weathers will recall. Maybe Bill Pawlik too. We'll see.
Yet as revenue surged, corporate excess began to warp the culture from 2014 to 2019. Compliance‑mandated events transformed into alcohol‑fueled sprees even though the CEOs and CFOs and President of Hematology, Nadim Ahmed, did not drink given he is a devout Muslim. Redundant executive roles were created to absorb capital and reward insiders... but eventually eliminated quickly if they did not perform Up to Celgene Snuff. Celgene lost key operational lessons from its past as traditional “Big Pharma” executives flooded the organization, quickly overwhelming New Jersey’s constrained local talent pool.
Outside the office, personal challenges mounted which led to my own personal discovery and positive growth. In 2012, I began therapy to navigate severe family adversity, including my big brother Sean’s struggle with addiction and subsequent state imprisonment in Ohio. That process of personal auditing built an unshakeable resilience—unlocking a clarity that proved essential then and guides me today as
a middle‑aged healthcare executive raising two sons and a German Shepherd rescued from a New Jersey nonprofit in Rockaway.
For ten and a half years—from August 2011 until I walked away in January 2022—I sat at the intersection of biopharma analytics and corporate strategy. I watched Celgene grow into a $100 billion titan at its peak share price in September 2017, witnessed the fatal leadership pivots that doomed its independence, and saw executive liquidation and desperation replace scientific discipline and True Business Development Rigor.
Revlimid lost patent exclusivity in 2022, yet through complex generic legal agreements and contracts, prices for these legacy therapies remain artificially elevated. While patients face staggering financial hurdles and wait for next‑generation cell therapies, biopharma executive compensation continues to drive systemic healthcare inflation.
"Blood Money", my Celgene memoirs, is my literal autopsy of how that machine was built, how it decayed from within, and how a $74 billion buyout by Bristol Myers Squibb exposed the ultimate price of biopharma’s excess.
What we pay in our modern era is just a Down Payment for the Future - our Children. We can build a better one if we rethink what we spend on American HealthCare, why we spend it, and why health outcomes stagnate or worsen for the wealthiest country in human history.
The Last Trimester of 2011: my Honeymoon Months, Grandpa Andy, and Celgene's A.I: Automated Integretation, not artificiAl algorIthms
AKA The Late 2011 Chapter — Honeymoon Months, Grandpa Andy, and Celgene’s AI
The whole process moved so quickly it was as if I barely interviewed. It felt like a slam dunk after Shawn, the executive recruiter from Colorado whom Kevin and Max liked - not the Shawn Tomasello who ran Celgene’s US Commercial function - coached me on how to ace the Celgene interview process. I knew I liked my future boss Max from our phone interviews—and the company was fascinating. In June 2011, I interviewed with Celgene, and within weeks the offer came through. I knew I was going to accept it
I liked every person whom I interviewed with, I was able to prove that I was the Senior Analyst of Sales Operations their Marketing team needed, and Max had a real "big brother" vibe, explaining how the company was investing in both solid tumors and hematology oncology (both traditional <sold tumor> and blood-based cancers)... .. . . . :
There was no long waiting period at Celgene, no endless rounds of bureaucratic hesitation, no corporate double-talk. It was decisive, clean, and refreshing.
By August, after a quick orientation period at Summit HQ—which was very pleasant and led by an HR rep who looked just like Richard Dreyfuss from “Jaws” and “What About Bob?” (two of his classic films) —I was walking into the Berkeley Heights 300 Connell building with a badge, a desk, and the overwhelming feeling that my life had finally tilted in the right direction.
After years of grinding, proving myself, and fighting through noise and personal storms, a real company wanted me.
A real mission. A Full Team.
It was a place that felt less like a cold corporate entity and more like a fiercely loyal, high-stakes family—my Cancer "Biopharmily" (Biopharma Family). Walking onto that campus felt like stepping into full sunlight after living under the flickering fluorescent bulbs of a workaholic consultancy for the prior year and a half.
Those first four months at Celgene Corporation—August 2011 through December 2011—were my honeymoon period. Sweet, clean, intense, and deeply satisfying. It was the kind of stretch in a man’s life where he wakes up excited before the alarm goes off, goes to bed tired after a long commute each way, and knows that the work he is doing actually matters. I didn't care about my daily hour-long commute from Princeton to Berkeley Heights. It was easy to do when I loved my work and had Wawa stops along the way for caffeine and breakfast sandwiches (to go, of course—I am always running late when cancer patients are waiting).
New Jersey is a notoriously difficult state to live and work in. My doctor jokes that, in most American states, the clinical cutoff for high blood pressure is 45, but in New Jersey, you hit it at 35. Sure enough, I developed high blood pressure at a young age, grinding through the relentless pace of the Tri-State area. Exercise, clean food, and getting out into the sunshine help keep me in shape mostly these days, but back in the late summer of
2011, the adrenaline of the new role was all the fuel I needed.
Like every Cancer or Inflammation & Immunology (I&I) & Cell Therapy Warrior who had the privilege of walking those halls, I loved working at Celgene. I didn’t just like the job—I loved it.
I loved my Celgene people. Everyone came from a different background, brought a distinct edge to the table, and operated with a shared, urgent commitment to the mission. I loved the core problems we were solving: every single day I walked into the office, I was using my engineering and analytical skillset to help fight cancer. It was exhilarating, even if the daily commute from Princeton up to Berkeley Heights or Summit was a brutal, traffic-choked grind five days a week. And I choked through it.
New Jersey is weird because they won't let us pump our own gas; I felt bad for the gas station attendants who had to breathe in all that exhaust all day long (I now drive an electric vehicle which I can pump myself, which I enjoy like the G.O.D: Good Ole Days!). I would tip the good ones who made my regular stops more pleasant. Now, I can charge my own electric vehicle—which is nice—and I look forward to the day when those polluting gas-guzzlers are gone from New Jersey roads.
I loved the pace, which only accelerated as Celgene matured. And above all, I loved the culture, anchored by several unshakeable pillars: Passion for the Patient, Courage to Face the Unknown, and, if you wanted to, the Ability to Change Things. It was the feeling of being part
of an engine that was actively building, growing, and doing tremendous good for human lives while succeeding commercially.
To understand why Celgene worked during those golden years, you have to understand the culture leadership built. It was a Spartan culture—disciplined, demanding, and uncompromising on performance. It was shaped from the top by Bob Hugin and Mark Alles, two former Marines turned pharmaceutical executives who ran the company with tactical precision and absolute devotion to the mission. They set an incredibly high bar. Surrounding them was a leadership cadre of elite, battle-tested executives: Adam Waldman, Jackie Fouse, Nadim Ahmed, Shawn Tomasello, and so many others who were disciplined and relentless in their Execution.
Yet, alongside that Spartan Celgene Intensity existed one of the most unique organizational dynamics I have ever experienced: a "Big Sibling" Mentorship Culture.
If you didn’t have a strong network of mentors and trusted colleagues at Celgene, it was tough to get anything done. And if you couldn't get things done, it was impossible to justify your role and compensation. People who tried to operate as isolated islands or political players never lasted long; the culture naturally rejected them. But every person who made it at least a year at Celgene and earned that first positive review knew they had Made It. You were brought into the fold. You were mentored, guided, challenged, and protected by senior colleagues who treated you like a younger brother or sister in the craft. They were all amazing to work with.
That foundation stayed with me for nearly a decade. By working hard, solving immediate operational fires for the cancer patients we served, and stepping up to help out with I&I and Business Development analytics whenever asked, I was fortunate enough to work on virtually every exciting artificial intelligence and advanced analytics project at Celgene from 2011 all the way until we were acquired in 2019.
Over those years, I got to know the executives and dozens of wonderful colleagues on a deeply personal level. I got to meet their kids, watch their families grow, and be a person they could trust. This meant as much to me as anything.
Right as I was finding my rhythm in late August 2011, Hurricane Irene slammed into New Jersey. We battened down the hatches, just like when my family and I survived "The Perfect Storm" near Boston and the state took a beating—rivers flooded everywhere, roads were washed out, and the storm caused so much damage that it shut down Celgene operations for a week or two. But as soon as the waters receded and the power grid came back online, we were right back at our desks, locked in and moving at full speed. It was an early taste of Jersey resilience.
We didn't know it then, but Irene was just a dress rehearsal; Superstorm Sandy in late 2012 would be infinitely worse, crippling the state for weeks. Yet, living through those back-to-back natural disasters didn't break us—it ultimately strengthened our resolve, forged an even tighter bond across our teams, and proved just how tough we had to be to keep the mission moving..
The AI (Automated & Integrated / Artificial Intelligence / Awesome, Inspiring) Commercial Engine
I really could not believe that Celgene Corporation was paying me more money than the consultancies I had worked for, with better benefits and well-defined vacation time—that my boss, Max, once actually ordered me to use, telling me to stop emailing while on vacation (I admit it, I am a bit of a Workaholic)... to be their hacker.
Celgene had data everywhere and yet nowhere.
My formal title was Senior Analyst of Sales Operations and Marketing Support. But, really? I was the guy that everyone started coming to when they needed fast, technical solutions to analyze the data. I worked hard to win over stakeholders—not just my boss Max, and Kevin, but everyone whom our team worked with.
Max and Kevin thought they were just getting some Senior Analyst who would have trouble getting promoted—but they were getting much more. I was a White Hat Hacker back in the late 1990s. My dear friend of 30+ years, Vitaly McLain, introduced me to the legend known as chameleon (you can search for them online if you want more information about what cybersecurity truly is and how we really got started hacking in America 30 years ago).
At Celgene: here is what we did, and quickly, once Max hired me, downloaded all of the REMS information and business rules into Doug and me as we could handle in a 4 hour meeting, and then unleashed me to go to work and help provide Celgene with the analytical firepowerthat both he, Bob, Kevin, and Shawn knew we needed. Vic was great on the Abraxane Sales Ops brand team as their Senior Analyst—but he was not a computer engineer like me.
1. The Setup — REMS as the Vault
From my first week on campus, I realized Celgene was sitting on a goldmine of anonymized REMS data. As Mary once put it: “our REMS data is the lifeblood of this company”—Customer Care always helped us, and we always helped them—there was Only One Celgene, as Max often reminded us (the Abraxane integration was difficult… they are always difficult, believe me).
Every prescriber, every dispense, every refill pattern—scrubbed of identifiers but rich with longitudinal signals. The problem wasn’t the data. The problem was the silos. REMS was everywhere and nowhere at the same time. Leadership needed answers in hours. The system delivered answers in weeks. That was the opening scene of the heist.
For those of you who do not work in Biopharma: REMS is simply a Risk Evaluation and Mitigation Strategy database. The REMS program was the regulatory backbone that ensured Revlimid and Pomalyst were monitored closely and that people of child-bearing potential knew of its teratogenic effects to avoid another poor child being born of birth defects due to accidental exposure. You may know that both Revlimid and Pomalyst are derivatives of thalidomide (“Old Uncle Thal” as Bob used to call it; that was Kevin’s boss, before he left for Incyte in 2012).
Thalidomide was first made famous by Billy Joel’s iconic “We Didn’t Start the Fire” song. Otezla, which came years later, is also an analog of thalidomide. The awful Saturday Night Live parody commercial featuring that Canadian actor needed a lot of work, as an aside.
You will recall that Uncle Thal was a powerful drug that led to the modern version of the FDA thanks to Dr. Francis Kelsey’s heroism. But that was covered in the excellent book, Dark Remedy, which my friend Mouzetta personally gave me her copy of in 2012 after she visited our home office to learn more about what we did to help them all in the field.
Uncle Thal, Revlimid, and Pomalyst came with immense therapeutic power but severe teratogenic risks—and were prescribed and dispensed with absolute safety.
Every healthcare provider (HCP, including our CMO Doctor Zeldis) enrolled in the REMS program had a structured profile. Every patient was fully de-identified, anonymous, and scrubbed of any personal identifiers in strict compliance with HIPAA, yet remained trackable at the longitudinal data level.
We knew nothing about who these individual patients were personally, per the strict HIPAA guidance REMS Customer Care implemented, but through the anonymized data streams, we could analyze macro-level treatment patterns, refill timing, adherence rates, and duration of therapy across nationwide cohorts.
It was an incredible asset, but in 2011, it sat in disparate silos. Nobody had built an automated engine to synthesize it in real time.
2. The Break-In — Bypassing Legacy IT
Celgene’s legacy tools were slow, locked down, and built for a different era—just like when I worked as a contractor with a Secret Security Clearance from 2009 until 2011 or so. SAS access was restricted given the lack of the appropriate IT infrastructure - I was surprised as they hired me for my analytical and programming skills, yet they really needed my hacking or reverse engineering skills.
Python wasn’t Yet IT-Approved Software back in 2011 - they thought I was describing a snake that I had seen on the campus, and not an essential coding language. Tableau was a distant dream, a rumor. If I asked our Information Technology Business Partners about relational databases and Alteryx… Well, they looked at me like the alien I was.
We still had an Excel-based CRM, in 2011 - I mean that is the most basic of the basics in Any Company with a Commercial Arm that already had made Billions of Dollars! We also did not have a true Customer Master yet, and time was running out to get one thanks to the Federal Sunshine Act.
IT was, to put it bluntly, a massive bottleneck—aside from my friend and mentor Debra S, who was a responsive partner and eventually recruited by Shawn to help lead the data team under Marco years later.
So I bypassed the bottleneck. I built the ingestion engine in Microsoft Access, using raw SQL and VBA automation. Not glamorous. Not “super modern”.
But when you architect it correctly and tap directly into a company’s raw database, it becomes a battering ram. This was the moment in the movie where the hacker cracks the well-encrypted safe with a qubit.
3. The Overnight Job — Automated Insights
Once the ingestion logic was stable, I wired the whole thing into an overnight automation pipeline. Millions of de-identified REMS transactions flowed in while the building slept. Validation checks fired and I lined up perfectly to Barb’s IC Reporting. Logic stitched itself together. Attainment metrics recalculated.
Within a few days, the system had already automated the work of a full-time analyst—our National Sales Director Jeff had been counting the authorizations manually to try and estimate new patient starts and total dispenses for Revlimid; Max asked me to figure out a solution, and I delivered one.
This was AI: the gears turning, the locks opening, the code running automatically whenever myself, Max, or anyone from our broader Sales Ops team wanted to run the database - with the click of a button.
4. The Reveal — The National Prescription Attainment Tracker (via Email that could be read easily on an iPhone or BlackBerry)
At 6 a.m., executives woke up to a clean, automated snapshot of national commercial performance. No more waiting for the slow monthly Excel Data Summary Tool (which was great—but imperfect and static). No more guessing or waiting for Celgene’s executives. No more manual spreadsheets. The field teams finally had a compass. Brand teams finally had a pulse. Leadership
finally had clarity. This was the moment the audience realizes the con worked.
Commercial leadership loved it—Adam, Jeff, and Nadim all could tell Shawn exactly where we were tracking our revenue goal (or our “Sales Attainment”). Soon enough, my automated REMS processing was everywhere—and Shawn began receiving the emails too, I believe.
Shawn would ask Jeff M when we had a dip in new patient starts (NRxs), and then Jeff would ask me to explain what had happened which usually required a backend data investigation —I would send him an email summary, he would review, then forward it to Shawn. Jeff was a key mentor and a leader for us at CELG—he was ex-military, his wife was a tough Chicago police detective, and Shawn hand-picked him to lead the Celgene Hematology sales force.
Jeff was Irish, from Chicago, and as tough as they come—he grew up with four siblings in an Irish Catholic family and went to Brother Rice. My Northwestern football teammate Tim McGarigle, who is their defensive coordinator now, played at Saint Pat’s like my biological father did back before the Vietnam War.
I still joke with Big Bill, our Ivy League Heavyweight wrestler, that “we Irish” did quite well at Celgene—Mike M, a former Marine who joined Celgene years later and provided strong leadership during the Celgene integration to BMS, knows this too.
Bob Hugin, Mark Alles, Shawn Tomasello, Tom Cavanaugh, Peter Kellogg, Brendan Delaney, and others were all of Irish American descent, like me (this is just my hearsay recollection, so I hope none of them just have Irish-sounding names like Conroy or Gallagher or McCormick —but I do believe Mark spoke about his Irish grandmother once).
You of course did not need to be of Irish descent to thrive at Celgene, as Claudio Faria (Portuguese, like Stacy), Jackie Fouse (Texas), and
Nadim Ahmed (he has a British accent) can attest: you had to love fighting cancer, care about your family, and be Tough Enough to survive the Cauldron that is New Jersey biopharma.
Years later, the entire Abraxane sales force was folded alongside our Hematology Oncology portfolio under Jeff’s strong leadership. Jeff and Shawn knew that the sales force needed a Chain of Command and Structure to avoid the Wild West days of the Old Celgene.
Perhaps it was too militaristic or rigid for some. But Shawn had been hired years before by Bob and Mark to clean up Celgene and fix the Commercial Structure after her success at Genentech. And Shawn Did.
And Jeff was the right leader as the only military regional sales director that Shawn had on her team of 5 RSDs (who all used to report to her before Celgene bought Abraxane and had to mature as a Commercial Organization).
Regional sales directors no longer had to wait until the end of the month to understand their territory performance; they could see real-time momentum every morning. District managers could instantly spot slipping territories and deploy targeted support. And our field teams—the Hematology Oncology Consultants (HOCs)—could see exactly how their daily educational efforts translated into national progress.
People outside Celgene often referred to the field team as "pharma reps," but that label never fit who our HOCs were or how they operated. They weren't out there "selling a pill." They were clinical educators operating inside one of the most stringent and complex REMS systems in modern medicine.
They spent their days educating oncologists, hematologists, and clinical nurses how our FDA indications and how to navigate REMS protocols safely. They walked office administrators through complex dispensing workflows and stood as the first line of contact unless Celgene Patient Support had to step in to assist with coverage or copay assistance.
The best HOCs were Never Pushy. They were Trusted, highly respected Clinical Resources. They focused entirely on provider education, built deep professional rapport, brought food to busy clinical teams working long hours, and made themselves indispensable to physicians trying to secure life-saving blood cancer therapies for their patients.
5. The Second Job — The Refill Rate Tool
Duration of therapy (DOT) was 95% of our business, but nobody could model it cleanly. Refill gaps, drop-off curves, adherence patterns—all buried in noise. So I built the Refill Rate Tool. In Excel. With no VBA. Just formulas long enough to make a grown analyst cry.
Max was able to run it dynamically in a meeting once, on the fly, with Shawn to show her how Revlimid’s duration data matured and answer her questions, and he told me She was Impressed—she rarely was in with our group in those early days; she knew we had the people, and now she and Adam and Jen H from the Multiple Myeloma brand team were getting their questions answered quickly and without waiting on management consultants.
That simple-yet-intricate Excel tool helped teams isolate dynamic cohorts, track refill gaps, and visualize adherence over time—using only formulas, no VBA, which was quite the tricky ask (I did not want a VBA program breaking down on Max whenever Shawn or Adam needed an explanation on our duration trends). This was the side heist—the unexpected job that makes the main job possible.
6. The Masterstroke: Kaplan-Meier Survival Analyses
Multiple myeloma patients often pause therapy for stem-cell transplant. Without modeling those gaps, duration curves looked broken. With Kaplan-Meier logic applied, they became clinically accurate. So I worked with Max and Victor to build an automated survival analysis pipeline—a PROC LIFETEST-style engine in SAS that finally gave leadership a true view of how long patients stayed on therapy when we applied it over the Commercial REMS data.
This was the final twist—the moment the audience realizes the protagonist wasn’t just cracking safes… he was rewriting the entire playbook.
Shawn told us very explicitly: she wanted One Number for our Revlimid and Pomalyst duration so that she knew exactly what was happening, like the European marketers were providing her from expensive market research.
So, we created a new mathematical process using the same methodology that our medical colleagues used for clinical trials—Kaplan-Meier was an engineering process that was used to predict when parts would fail. KM Survival Analyses are used to assess the outcomes of clinical trials— while I am not a biostatistician, I know enough to get by.
7. The Payoff: Celgene Takes AI - Analytical Integration, not Artificial Intelligence - Seriously
By the time the system was fully operational, Celgene’s commercial engine had transformed. Real-time intelligence and updates from our internal REMS data—and eventually the other syndicated feeds too. Automated analytics. Daily visibility. Clinical alignment. Operational precision.
People stopped calling us “Ops”. Our Marketing and Market Access colleagues who needed our support then started inviting us to meetings, asking us to present monthly or weekly updates—especially the KPIs (Key Performance Indicators, or “Key Metrics” on our many product launches).
Our Commercial Executives started Expecting us to Walk the Strategic Journey with Them and Their Teams. And that was the payoff—the moment the Conroy Method of Working became the New Normal.
Sales operations had been viewed as part of IT before I arrived—now, with a lot of teamwork and dedication, we became essential as strategic insights partners.
Marketing needed us as well as market research and competitive intelligence. This was a huge turning point for our brand—eventually, we were relocated from 300 Connell to Berkeley Heights—where we belonged!
From my very first week on Celgene’s campus, I was given work that actually mattered. My primary responsibility was automating the endless stream of complex analytical requests coming directly from senior leadership, or coming up with creative analytical solutions when we needed answers, and quickly.
We were creating an early operational artificial intelligence long before "AI" became a ubiquitous corporate buzzword because of ChatGPT and Google.
Celgene felt right. It felt purposeful. It felt like I had finally found my professional home in Summit, New Jersey. I was as happy as a clam, making many interesting friends in Princeton, New Jersey where I lived in a rented floor upstairs from a house full of Princeton PhD candidates—mostly fellow engineers.
Life was very good in 2011. All of it. The entire year rewarded me for what had been a difficult 2010... but that was B.C. (Before Celgene).
The Loss of Grandpa Andy our Polish Panther from World War II
Then, two months into this incredible honeymoon period, life delivered a sharp, unavoidable reminder that pure joy rarely exists without a
shadow.
My Grandpa Andy became God’s Latest Angel in late 2011, right after I joined Celgene.
It wasn't a sudden or tragic death in the traditional sense—he was 92 years old, having lived a full, incredible life. Born in 1919, Andy was a giant of a man from a bygone era. He dropped out of high school as a teenager to go to work and support his family, likely living with undiagnosed dyslexia, but possessing incredible natural intelligence, boundless patience, and an unshakable work ethic.
He was a legend. Grandpa Andy wasn't just my grandfather; he was a living, breathing piece of American history walking around in human form.
Back in his younger days in Chicago, he looked like a statue—built like a "Polish Panther," or "the Polish Puma" as my brother used to call him (based on the Spider-Man comic book character—I read a lot of comics, and my siblings borrowed them from time to time). Grandpa Andy was broad-shouldered, sharp-featured, and rock-solid.
When World War II broke out, the manufacturing plant in Chicago where he worked was immediately converted into a military weapons production facility. He was a tool-and-die maker before WWII, and he resumed that exact job for the duration of his career. That was how America operated in those days: no endless debates, no corporate posturing, no complaining. The nation was called to serve, and everybody answered.
He was a bit older when he was formally deployed into the European theater—around 24 or 25 years old. Because he grew up speaking fluent Polish in his Chicago neighborhood, the U.S. Army quickly realized he was useful in ways standard infantrymen weren't. He was deployed into specialized roles as Allied forces pushed through Europe.
When American troops liberated the concentration camps—when those gates were forced open and the incomprehensible horror of the Nazi regime spilled out into the cold daylight—Grandpa Andy was one of the many American soldiers sent in to secure the sites, translate for survivors, and help clean up the horrific aftermath.
Our sweet, gentle Grandpa Andy witnessed things no human being should ever have to see. He bore witness to the absolute darkest depths of human cruelty, and he carried those searing images silently for the rest of his life.
He never talked about it to me. He never talked about it to his own children or grandchildren. It was a burden he chose to carry in quiet dignity to protect us from that horror. I only learned the full truth years later, when someone else close to the family revealed what he had done during the war.
I was devastated when I found out—both by the weight of what he had endured and by the overwhelming desire I had to stand before him as an adult, look him in the eye, and tell him, "Grandpa, I made it. I'm doing work that matters." I never got the chance to say those exact words to him.
When he passed away in the autumn of 2011, my initial instinct was to arrange immediate travel to attend the funeral service. But my older brother, Big Sean, insisted that I drive out through Ohio to pick him up so we could make the long journey together. I resisted. I didn't want the logistical detours.
I didn't want the long, agonizing highway drive just to deal. I was locked into my new role at Celgene, operating at 100 miles an hour, and my compartmentalizing mind insisted on a simple plan: pray for Grandpa Andy’s angel to help me in New Jersey, where I so often need the Better Angels of my Nature. This is a Very Difficult State to Make It in (New Jersey, and the entire country of that is America.)
Underneath those operational excuses, however, lay a much deeper, more painful truth: I simply could not bear the thought of remembering my grandfather as ashes in some funeral home.
I didn't want my final mental image of that amazing man to be an urn sitting in a quiet, solemn room filled with hushed voices and open grief. I wanted to remember him vibrant and full of life—sitting across from me at the Oasis Diner, eating a heavy breakfast, telling stories from his youth, looking at me with those sharp, clear eyes, and saying:
"Juph-ree… I am so proud of you."
That was the man I knew. That was the man I loved. That was the man whose pride in me meant more than any corporate title, any bump in salary, or any analytical system I could ever build.
To replace those warm, vivid memories with the cold, sterile reality of a funeral felt wrong. It felt like a betrayal of the vital, unbreakable spirit that my World War 2 Veteran Grandfather had embodied for almost 93 years.
So, I made the agonizing decision to stay in New Jersey. I grieved quietly in my own way. I honored his memory by remembering him as the invincible statue he was. And then, I poured myself back into my work.
Celgene became my sanctuary, my focus, and my purpose. I was emotionally raw during those weeks, and my colleagues naturally noticed it. I didn't try to hide my grief behind a corporate mask; I simply explained that my grandfather had passed away and that in my core belief system, Family is Family.
My boss Max and his boss both reminded me that Celgene offered bereavement leave, urging me to take all the time I needed. But I declined. I knew in my heart that Grandpa Andy loved nothing more than seeing his family work hard, build something real, and push forward through adversity. He didn't believe in sitting still or wallowing in sadness.
He always loved hearing about my work. The only time he ever yelled at me was when I quit Motoman Yaskawa (where I programmed robots for $11 per hour during my amazing summer internship in 2004) to join the Early Identification Program at GE Healthcare in 2005 and kickstart my career in healthcare. He calmed down when I told him, "I'm getting paid almost double to move to Milwaukee and work on healthcare ultrasound systems."
He paused and went, "Double?!" "Yeah, double!" I said. He immediately calmed down, thought about it, and told me to stay away from the north side of Milwaukee "where all the Germans were."
Keep in mind that Grandpa Andy was a first-generation Polish American who fought for the U.S. in World War II. He was from a different era and never trusted Germans after what he saw in Europe.
He was always proudest when he knew I was working hard, which I love to do (work hard).
So, I stayed in New Jersey and kept working. Celgene was happy to have me, and I was happy to finally have my biopharma family in Summit and Berkeley Heights.
My Orlando Reset
The honeymoon period rolled on through the remaining months of 2011. The analytical projects kept expanding. Commercial teams continued to adopt the tools I was building. Legacy Celgene veterans expressed genuine appreciation for the operational momentum we were creating, while more and more new hires arriving on
Celgene’s campuses brought fresh energy. The culture continued to feel like a rare, special ecosystem where an ambitious engineer could build a meaningful, lifelong career.
Yet, as the calendar turned toward the holiday season, the atmosphere shifted. It wasn't catastrophic or dramatic—just noticeably heavier.
The unresolved grief over Grandpa Andy’s passing, combined with the quiet chill of a Northeast winter and the subtle emotional weight of the funeral I hadn't attended, began to settle on me. I remember sitting alone in my apartment after a long day at the office, looking out at the cold New Jersey night, thinking: I need to get out of here for a minute. I need to go somewhere warm, quiet, and cheap. I need to disappear and reset.
I booked a last-minute, low-cost trip down to Orlando—searching for warm air, a pool... Anonymity. I didn't want luxury or entertainment; I just wanted a quiet floating pool, a stretch of Florida sunshine, and complete privacy where nobody knew anything about me.
A space to breathe, reflect, and reset my mind before stepping back into the fray.
By the end of December 2011, my day-to-day work at Celgene had become second nature—not because the problems were simple, but because I had developed immense confidence in my ability to execute. The honeymoon period was still in full flight. I was solving critical operational challenges, building deep mentoring relationships, mastering the intricacies of oncology commercial analytics, and earning the respect of leaders I deeply admired.
Work felt like a privilege. On many days, it felt as energizing as a paid vacation because I was surrounded by brilliant people working toward a noble cause. I would pour everything into the job during the day, relax in the evening, and feel a deep sense of gratitude that my life was finally built on a solid, meaningful foundation.
Yet, beneath all that sweetness—beneath the warm Florida sun, the bright Celgene glow of an amazing professional career, the appreciation from my peers, and the rising momentum—something darker was quietly beginning to form on the horizon.
Strategic shifts were brewing at the highest levels of the industry that would hit us hard in 2012—along with Hurricane Sandy later that year, which was destructive and transformative for the state. Unseen pressures were building around pipeline longevity, generic timelines, and corporate deal structures that would eventually transform the entire biopharma landscape.
The seeds of strategic overreach were being planted, and the pristine, familial culture we cherished would soon be tested by unprecedented commercial demands.
I didn't know it yet. I couldn't see the long-term arc from where I stood in the winter of 2011. I thought I had "made it"... but I was nowhere near where I needed to be, either professionally or personally. I needed help for my
depression, which I wouldn't realize until 2012—a very difficult but transformative year for me personally.
I didn't realize that this calm, productive stretch was the closing chapter of a simpler era—the last quiet calm before a chaotic, decade-long storm of high-stakes corporate and New Jersey evolution. But for those four magical months from August through December 2011, life was unequivocally good. Life was clear. Life was hopeful.
It was the ultimate biopharma honeymoon, and the finest stretch of "pure joy work" before everything began to change and I got serious about making Blood Money at Celgene in 2012 when things got tough, and we toughened up as a Sales Operations, Insights, and Analytics team.
Neither Hurricane Irene in 2011 nor Hurricane Sandy in 2012 would ruin New Jersey—nothing can ruin New Jersey. We are the Garden State and Biopharma Tough.
New Jersey is the Healthcare Center and Medicine Chest of the entire World, and it has been for centuries.
Don't worry, we will get there.
The 2013 Chapter — The Women Who Truly Ran Celgene Could Not Overcome Leadership's Addiction to BD (BAD DEALS!)
2013 didn’t arrive politely. It didn’t knock. It didn’t wait for me to be ready. It kicked the damn door open, walked into my life uninvited, and immediately started rearranging the furniture. It was the year I learned that adulthood doesn't care about your schedule, your therapy progress, your emotional bandwidth, or the weight you're already carrying. It comes when it comes. And in 2013, it came hard for me.
I entered January thinking I was finally stabilizing—therapy underway, career rising, routines forming, the emotional fog beginning to lift. But beneath the surface, something else was shifting: neurological symptoms, dizziness, imbalance, and fogginess that were early warning signs of a traumatic brain injury suffered in childhood. I didn't understand any of that yet; I only knew I felt off. But life didn't pause for my confusion, and January meant San Antonio.
San Antonio: The Desert, the Boots, and the Cramping
The 2013 National Sales Meeting in San Antonio was my first true national meeting—the first time I saw the entire commercial organization assembled in one place. I still have the cowboy boots from that trip, a reminder of the desert heat and the surreal mix of oncology seriousness and Texas pageantry at Celgene’s sprawling Marriott resort.
The Hematology reps were the heart of Celgene back then—driving 80% of the revenue as culture carriers living and breathing Revlimid and Pomalyst, while Abraxane solid-tumor reps were still finding their identity. Between strategy sessions, card tricks, fake casino tables, and magic shows, I bonded with Tom, met more HOCs, and tried to stay hydrated. But no matter how much water I drank, I kept waking up with brutal cramps in the dry heat. San Antonio was the first crack in the year—the first sign that something was off.
The second crack came in May.
May 2013: The Night Everything Went Sideways; I was arrested for DWC (Driving While Concussed)
I had planned to crash at my sister’s apartment in Pittsburgh after a long drive, but she needed space, so I drove the final two hours to Ohio, exhausted and foggy. Meeting up with friends to watch the Indiana Pacers play the Miami Heat, my neurological symptoms hit me at the worst possible moment.
The arrest that followed was humiliating. I didn’t understand why my speech and balance were failing me, or that these were neurological symptoms rather than behavioral ones. I hid it from work, friends, and myself, having no vocabulary yet to explain what was happening. But Celgene didn’t slow down for my crisis.
Kansas City and the Summit Reset
During a field ride in Kansas City with Scott—widely regarded as the best oncology sales educator in Missouri—my pants split clean in half on the tiny plane, a fitting metaphor for a year coming apart at the seams. I spent the night sewing them back together, and despite the chaos, the field ride was excellent. Scott delivered a line that stayed with me:
"There has never been a better time to be a Multiple Myeloma patient."
By mid-2013, I needed stability and moved to Summit, New Jersey, through an unofficial Catholic network—John and Peter—who offered me an apartment based purely on trust and cash. John, the Italian landlord whose father died in Okinawa in 1943, treated me with unexpected kindness. Summit gave me quiet streets to walk, neighbors who cared, and a sense of belonging I hadn't felt in years, including a memorable afternoon when I helped a legally blind elderly neighbor who had suffered a stroke.
Shawn's Pastor and the Fast Track to First Dispense
The real turning point of 2013 wasn't in San Antonio, Ohio, Kansas City, or Summit. It was in Celgene Patient Support (CPS)—the beating heart of the commercial engine where patients were approved, verified, and authorized. In 2013, CPS was drowning.
Celgene was growing too fast, and the infrastructure underneath was cracking.
Patients were waiting too long to start therapy, and Shawn Tomasello—the Dragon Queen from Ohio—was Not Too Happy about it. Inspired by her pastor's subcutaneous Velcade experience, Shawn demanded to know why Revlimid verification and prior authorizations were causing bottlenecks.
Working out of my tiny Summit office, surrounded by stacks of CPS forms and messy data extracts, I mapped every step, form, fax, and prior authorization to build the Fast Track to the First Dispense analysis. Jeffry Gype—one of the tough, grounded Ohio guys—and others kept me laughing as we worked. The Duration Analysis proved that analytics could literally change lives by reducing wait times so patients could start therapy sooner.
Shawn saw the work, the numbers, and the clarity. That was the year Shawn started giving me her time, advice, and mentorship, treating me like family and giving me her trust.
BD Addiction, Operational Brilliance, and Falling in Love
The second half of 2013 was a paradox: the most chaotic stretch of my professional life and, somehow, the most stabilizing.
Celgene’s operational backbone was built and truly run internally by women—Jackie Fouse and many other female leaders who kept the commercial engine aligned, the field teams sane, the analytics grounded, and the culture human. They understood how the machine actually worked.
And yet, as 2013 progressed, Business Development stopped listening to them. BD became addicted to options, lottery tickets, risk stacking, and the adrenaline rush of deal-making—a casino mentality disguised as strategy. They were chasing assets that didn't fit the commercial engine, ignoring operational warnings from the women who actually ran the place, hoarding early-stage options, and treating patient support like an afterthought while burning capital faster than Jackie Fouse could impose discipline.
Thanksgiving in Edison — The First Time New Jersey Felt Like Home
Amidst this corporate shift, shortly after my thirtieth birthday, I met STACY. We fell in love quickly during the cold 2013 winter, and her mom invited me to her extended family’s Thanksgiving in Edison. Her mother Linda and her aunt MaryJo welcomed me like family, seeing only a man their daughter cared about rather than my past or the storms I was still navigating. The loud, warm, joyful house made New Jersey feel like home for the first time on a personal level, and Stephanie’s steadiness anchored me.
My Promotion During the Commercial Operations Re-Organization and the Return of Momentum
Around the same time, my first CELGene Boss Maxim transitioned into the field, making sure my work was recognized before he left. I was promoted to Manager of Commercial Operations. Celgene still believed in me, seeing the potential and leadership qualities I was growing into while operating quietly in the background.
Looking back, the second half of 2013 was the hinge point. My personal world was clearing up and I had found a wonderful grounding partnership with Stacy, but corporately, Celgene's BD addiction was accelerating, operational leaders were sidelined, and the culture began drifting from disciplined oncology execution toward high-risk deal-making.
It was messy, beautiful, and formative—the year I learned that life can be sweet even when it's complicated, and that sometimes the most important stabilizing force arrives quietly, in the form of a Partner and Future Dragons who made New Jersey feel like Home.
(The 2013 chapter was much shorter than it should have been. We had to get the book done without getting a lawsuit or three.)
2014: The Final CELG Split & Charlie Arrives
2014 was the year everything tilted for the better—the year Celgene changed, the year I matured, the year the cracks began to show in Celgene's foundation after the Company's final stock split, and the year I finally understood what it meant to do the next right thing and become an Uncle even when the world around you was spinning.
It was the year of the final stock split, the first true organizational restructuring, the depth of falling in love, the profound joy of becoming an uncle, and the year I watched people I cared about graduate from the Cauldron—that intense Celgene pressure cooker that forged some of the sharpest leaders in biopharma. It was also the year a boss brought a baseball bat to work. But we will get there.
Celgene had been growing fast—far too fast. The company was still operating with the frantic energy of a scrappy oncology startup, but its revenue curve looked like a Fortune 50 rocket ship. We were a massive corporate titan pretending to be a middle-school science fair project, and something simply had to give.
That something arrived in the form of Marco, a former Swiss military officer and Johnson & Johnson executive. He walked into Summit with the calm, disciplined presence of someone who had seen real corporate warfare before and refused to be intimidated by our local chaos.
Like both Kevin and Nadim and Shawn, Marco did not raise his voice, posture, or need to micromanage. He understood systems, he understood people, and he understood that Celgene needed a Commercial Operations function that actually matched the scale of its business.
For the old guard who had built Celgene on whiteboard scrawls, midnight coffee, and sheer adrenaline, Marco’s arrival was a cultural shockwave. It marked the exact moment scrappy Celgene Commercial Operations startup grit was forcibly replaced by Fortune 50 corporate machinery to better support our patients who were battling cancer.
The reorg began quietly—a few late-night executive meetings, tentative org charts circulated in secret, hallway whispers at 300 Connell—but by early 2014, the writing was on the wall: Celgene was continuing to rebuild itself, and bureaucratizing the operational backbone we had improvised.
Amidst that seismic structural shift, I had been promoted to Manager of Commercial Operations at the end of 2013. It was the first time I felt truly respected given how much sweat equity and maturity it required.
After years of building early data engines, automating REMS analytics, and trying to drag Celgene into modern computing through sheer engineering force, leadership finally acknowledged that analytics was not a nice-to-have luxury. It was infrastructure, strategy, and the future—and they invested in us.
Reorgs create movement, and 2014 was defined by it as people I cared about all Graduated from the Cauldron and moved into roles fitting their strengths and ambitions. It became pretty clear to our Executive Leadership that we needed to invest heavily in our Information Technology department after I struggled to get anything done for nearly 2 years. Kevin left to lead important projects as a Senior Director in IT and improve the entire company’s data analysis potential - eventually he won significant investments from our CEO Mark Alles to try and help Celgene evolve “into the big data age”.
Steve and Max both interviewed for and were hired as Hematology Oncology Consultants in New Jersey, proving that Celgene’s culture could elevate anyone who worked hard and genuinely cared about patients, regardless of whether they fit the traditional sales rep stereotype - both of them thrived in the field for CELG and moved on to other roles as their developmental interests shifted.
I had a new boss in “Flip” (a pseudonym, of course) - a nice guy who was newly engaged to someone at the company. Flip was an Introvert like Me. Flip was an excellent musician with two cats, and we got along well. We hired a colleague of his from Kansas to replace Steve who did great work for a couple of years before moving onto the field. While a number of people had graduated (or left Sales Operations) as we were rebranded into Commercial Operations to reflect our growing partnership with the Overall Structure and relocated from 300 Connell in Berkeley Heights to Summit in late 2013.
To replace Kevin as Senior Director, Shawn tapped one of her most trusted confidantes from the field: Andrew, who had worked with her in Sales Operations at Genentech and was one of the Abraxane Regional Sales Directors. He lived about an hour from the office and was both an experienced Pharmaceutical Executive, a budding football coach, and a father of three kids about my age - two boys and a daughter whom he lovingly called “Goose”. I did not realize it then, but leadership realized that I and most of Sales Operations were former athletes - so hiring people like Andrew who believed in coaching was key. Andrew, Flip, Anthony, Mary, Sheline, Virginia, and I had some very interesting team meetings on Hematology.
Andrew had started winning me over at the 2013 POA, when he told me “that he had heard good things about me” - which is New Jersey parlance for, “Jeff M and Shawn told me you’re smart”. When he joined us in 300 Connell as ‘the new Sheriff in Marco’s town’ - which was hilarious, and HR condemned him for - Andrew took one glance at my work. He then told me: “Jeff… do you realize you saved Celgene MILLIONS in consulting fees?”
I told him: Yes, Yes I did. But Andrew did not realize how much that impressed me. He was an Italian Stallian, alright. A real Bruce Springsteen… Only he joked that he didn’t like Irish people (Andrew was a Yankees fan and kept an autographed Derek Jeter picture on his wall; I still don’t think he knows that Bruce Springsteen is half-Irish and half-Italian, AKA New Jersey’s “most common Catholic mix”.
Pete moved on to Novo Nordisk, making the right choice for his young family to ease a brutal commute and support his family closer to Princeton. I miss Pete; he invited me to Thanksgiving in 2012 when he knew I was dealing with some family difficulties (Grandpa Andy’s death and Sean’s incarceration caused me a deep depression).
I hope Pete and his daughters are doing very well. I recall that he adopted them and “knew by the time that they were in first grade that they are way smarter than him”; I know the feeling whenever I hang out with my kids and their friends, these days. This next generation of minds will do things we can not even comprehend. I’m so excited to find out what my kids will end up doing and try to support them closely while they are young.
Jill from the data team got engaged and left Celgene; she chose to focus on being a stay-at-home mom after an incredible journey from Patient Support to Data Management (Celgene was getting more intense as it matured as a company). Virginia kept leading the data department, with my dear friend Sheline reporting to her. I think Virginia is still with “the firm”; Sheline moved on to Novartis after Celgene (AKA our “big Swiss brothers to the North”!).
Vic—the original Senior Analyst pioneer who paved the way on the original REMS analyses and Dose Modification views before I arrived and proved “Celgene needed more analytical firepower” before I was hired —was recruited into an incredible contracting role in Market Access. It was a year of movement, growth, and evolution, where people were not just leaving Celgene; We were Leveling up and “Graduating from the Cauldron” in order to both grow within the company and also help other departments mature in their understanding of our incredible data and how to best use it to support our cancer patients.
Finally, my close friend and mentor who had sales and market research experience on Abraxane - Jen M - moved over to lead our Solid Tumor Sales Operations and Analytics function. Jen recruited her acolyte and my friend, Jessie T. Jessie was a key hire for Sales Operations to grow and evolve: she had a Master’s Degree in Statistics and we had known each other at our prior consultancy before joining Celgene in 2011. She had two kids and was bored in her old job, and we knew she could do more for Celgene under Commercial Operations.
Sales Operations needed More Statistical Brain Power, and Jessie had Plenty of it. I’m still glad she joined, even if she didn’t enjoy being my Direct Report in 2015 prior to the Hematology & Oncology merger in the US under Tom’s strong leadership. I have not seen Jessie in over a decade; her husband is a lawyer, and she left for Bayer years ago.
So, while Commercial Operations lost Max and Steve to the field and Kevin to IT, we added Andrew directly from the Abraxane Sales Force, we recruited Jessie to add more statistical firepower (she had a SAS license and knew how to use it!), and we landed Jen M who had both a cunning instinct plus the “soft skills” needed to help the team rebrand ourselves. Jen was also Craig P’s favorite employee as far as I or anyone could tell - she had sales experience, market research, and now was joining Commercial Operations - and she knew how to get work done.
The true test of our new team structure came in the brutal weeks leading up to the National Sales Meeting (NSM). The fight before the NSM was a high-pressure crucible of late-night scrambles, heated arguments in windowless conference rooms, and intense operational friction. We were re-engineering territory alignments, rep credit logic, and field target lists under tight deadlines while executive leadership demanded perfection. The old way of doing things—last-minute spreadsheet fixes and manual patches—was buckling under our rapid growth as a company.
Marco and the newly aligned team worked hard, pulling order out of complete chaos. We circled the wagons, absorbed the heat from anxious field directors and marketers who needed updates and data insights as quickly as we could offer them, and delivered a bulletproof operational framework before taking the stage. We proved that Commercial Operations was no longer a back-office utility, but the tactical command center holding things together.
That operational evolution was mirrored in corporate finance when Celgene executed its final stock split—a two-for-one split. In practical terms, if a share was trading around $160, it became $80, and owning 100 shares meant holding 200, leaving total portfolio value unchanged while halving the nominal price of future stock options and RSUs. Leadership did not sugarcoat the dilution; they told us honestly that this was the price of growth, and they were right, as Celgene’s stock soared from 2014 to 2017.
We had proven to senior leadership that analytics infrastructure mattered, and they rewarded us. Yet, the split served as a quiet, golden-handcuff trap. Doubling option counts created the psychological illusion of wealth creation, locking mid-level managers and directors into a quieter compliance. It kept everyone ‘handcuffed’ to their jobs in a way, ignoring the growing cultural cracks and pipeline vulnerabilities because our brokerage accounts kept compounding. It was a stark reminder that Celgene was no longer a scrappy startup fighting for survival—it was a full-fledged corporation, and corporations always protect the balance sheet first.
Looking outward at Business Development, 2014 proved to be a year of mixed bets that mirrored the company's broader trajectory. The Acceleron partnership for luspatercept (Reblozyl) required a $25 million upfront investment and yielded a blockbuster crown jewel with peak sales reaching $2.3 billion, proving Celgene could still pick winners when grounded in deep science.
Other BD deals yielded more modest or complicated results, such as the Sutro antibody-drug conjugate platform and a second Forma protein degradation deal. It was a microcosm of Celgene itself: brilliant bets that paid off alongside expensive early-stage gambles that evaporated into thin air, as a company tried to buy its future on Wall Street while simultaneously trying to build it internally. Celgene’s addiction to BD was quietly growing, and the cracks were starting to show, but the machine was generating so much cash that nobody wanted to stop the music.
Professionally, 2014 was the year I grew up; personally, it was the year I fell in love. Stacy was not just a girlfriend and future wife; she was the person who made New Jersey feel like home. Working as a psychiatric social worker meant her heart was in the right place and she grew up in Union County before eventually returning for her master’s degree in Social Work at Rutgers.
Stacy understood the Celgene mission, the pressure, and ultimately, she understood me. By 2014, I knew she was the one. We spent weekends in Morristown, sharing dinners with her family and quiet nights talking about life and the future, warmly welcomed by her mother-in-law Linda and her aunt MaryJo as though I had always belonged.
Then, at the end of the year, Charlie was born—Stacy’s niece, the daughter of her sister and Stacy's brother-in-law Jon (whom I admired like few others in life). Charlie was an angelic little baby and deeply loved. The moment I held her—this tiny, 6-pound miracle who felt light as a feather—it struck me with visceral clarity.
While I spent my days inside Celgene analyzing spreadsheets designed to squeeze maximum yield out of specialty pharmacy pipelines and commercial operations spreadsheets, here was pure innocence. Charlie instantly established herself as an important anchor of our lives, a living reminder of what truly mattered, and someone for whom I desperately wanted to be a role model. She was one adorable baby.
Every company has its legends, and Celgene was no exception, though few could rival the sheer, unhinged drama of the baseball bat incident. My Boss Flip, a brilliant and intense boss who was dealing with immense personal pain and suffocating pressure inside the Summit pressure cooker, finally snapped when he discovered a colleague named Stew was having an intimate relationship with his fiancée, who also worked at the company.
In a raw demonstration of His Masculine Rage - some would call it a breakdown, but most Men call it a Passion to Protect the Woman you Love - Flip brought a wooden baseball bat to the garage looking for Stew. Celgene’s Security Intervened.
It was the ultimate, terrifying proof of how unmanageable the burnout and psychological stress inside Celgene had become—where personal lives and corporate pressure collided until the structural seams burst open.
Flip then took twelve weeks of medical leave on the company dime (At Full Pay!), returned as if nothing had happened but with his Depression + Anger well managed, and in a twist of surreal workplace irony, was briefly managed by me before the 2016 reorg. Flip was smart. Flip Earned a Lot of Respect by bringing a Bat to Work.
He eventually quit Celgene voluntarily in 2017 to travel the world. It was an impressive move born of human suffering and depression, and a blunt reminder that even inside a $100 billion oncology machine, the people driving the gears are fragile and human. Flip, like me, was a big white guy with a beard who was not from NJ with a sensitive soul.
Now, as a man who was newly in love with Stacy… I still Respect Flip for sticking up for himself and his fiancee, even if a bit overboard with bringing a baseball bat to the office to beat up the guy (who, frankly, deserved it if he knew she was engaged), and also for leaving Celgene on his own terms.
To add a final touch of absurdity to the era, shortly after Stacy and I saw “The Wolf of Wall Street”, I received a cold call on my cell phone from an investment guy named Jordan B. He sounded just like a young Leonardo DiCaprio trying to pitch me penny stocks and financial garbage.
I hung up immediately and laughed my ass off in my cube, but it was one of those surreal moments that captured the spirit of 2014—a world where corporate excess, wild finance, and unbelievable reality walked hand in hand.
My lesson from 2014 was that life does not necessarily get easier, but it does get clearer—and better. You do not control corporate reorgs, BD gambles, stock splits, baseball bats, heartbreak, or the unpredictable chaos of the future. You only control yourself: What is the Next Right Thing to Do?fwfwwfwfw
In 2014, I focused on doing just that: I worked hard, loved deeply, supported my team, grew professionally, became an uncle, became a better man, and stayed fiercely loyal to the mission, the patients, and the people who mattered.
It was not a flawless year, but it was deeply formative. It was the year Celgene matured, when I fell deeper in love, and everything tilted back in the best possible way.
2018: The Year Everything Changed: Jon went to Heaven, We became Pregnant at Celgene, and I worked on Becoming a Father
There was a strange, hollow expanse to the calendar year 2018.
When you look back at it across the expanse of time—standing now in October of 2026, with two sons shouting down the hallway and the graying temples of a man who has survived corporate warfare, profound personal ruin, and the slow-grinding gears of life—2018 looks less like a year and more like a car crash caught in slow motion. It was not a good year. It was a Mess of a Year. It was not a triumphant year. It was an epoch of absolute fracture. It was the twelve-month crucible where everything I thought I was, everything I had built at Celgene, and everything I understood about the universe was systematically taken apart, hammered on an anvil, and reassembled into something entirely unrecognizable.
For the longest time, I barely remembered the sequence of it. The days bled together into a gray, suffocating smear of hospital fluorescent lighting, commuter trains crawling out of Basking Ridge toward Summit, silent kitchen tables, and the relentless, gnawing background radiation of grief. The human brain, in its mercy, builds scar tissue over the worst of its trauma much like the CTE that has left portions of my forebrain scarred but not permanently damaged... I hope... leaving only jagged monuments behind. The monuments of 2018 are etched into my soul like so much acid: Jon’s death in April, our pregnancy swelling against the backdrop of an uncertain future, the final, pathetic spasms of Celgene’s business development engine, the vultures circling the Summit headquarters, and the terrifying, beautiful, ego-shattering realization that my own life was no longer about me.
Jonathan Lawlor of Bucknell University, Castleton Commodities International, a dear friend of Portugal's Miguel Simoes and many others, and New Providence School District's Eagle Scout became God's Latest Angel on April 10th, 2018, just one week before his thirty-seventh birthday. Thirty-seven (37). To a man approaching forty-three (43), thirty-six is a young man; it is a long hike, many eggs and apples and cups of coffee, the prologue of a life. But Jon was gone. He died quietly, painfully, bravely, travelling as the hospice nurse put it, and with the kind of dignity and peace that makes people like me feel smaller. He was my Chosen Big Brother-in-Law, but he was more than that—he was the anchor of our family, the steady hand on the tiller, the electrical engineer from New Providence High School and Bucknell University and then a great company in Connecticut who saw the equations of the world with crystalline clarity. He loved Shakespeare’s timeless verse, the grit and glory of the New York Yankees through every summer, and the honest, piano-driven truth of Billy Joel records spinning in the quiet hours. He loved his daughter Charlotte and his entire family with a ferocious, unfiltered, yet gentle devotion. When Charlotte was born, Jon understood instantly and completely that his own ego had expired. He knew without being told that he no longer mattered. His purpose was her. His breath was hers.
His future was hers.
I didn’t understand that truth when it happened. Not really. Not in my bones. I was too green emotionally. I was not yet a father myself—just a young Fun Uncle who had a niece that had just received an unimaginable void where her True Father should have stood due to colorectal cancer. I was too busy fighting the louder battles of the corporate suite, too obsessed with the metrics of biopharma analytics, too trapped in the delusion that my professional survival, my personal horsepower, and my battle-scarred pride were the center of gravity. It took the combined weight of Jon’s casket sinking into the Ohio earth and the miraculous, terrifying heartbeat of an unborn son to finally shatter the stained glass of my self-absorption.
The months immediately following Jon’s funeral were utterly surreal. I went back to work because big strong people like us don't know how to do anything else; we put one foot in front of the other because the mortgage doesn't care that your heart has been ripped out of your chest. I went back to Celgene Corporation, our brand new L building in Summit. I went back to the building where the golden era had already curdled into corporate panic. Nobody needed to pull me into a conference room and whisper secrets; I didn’t need an insider memo to know the writing was on the wall. We were too cheap, our pipeline was too erratic, and our desperation was bleeding through the floorboards.
The larger biopharma sharks were circling Summit, and the blood-favored water was finally turning beet red in New Jersey.
If you want to understand why Celgene Pharma got bought, you have to look at the structural rot of its final years—the desperate, multi-billion-dollar bet-hedging that we chronicled in the ledgers of Appendix A. The BD deals executed between 2012 and 2018 were supposed to be the salvation of the company, the magical pipeline extensions that would rescue us from the impending Revlimid patent cliff. Instead, they became a monument to executive terror. Celgene had burned through $22.8 billion in upfront cash and equity across those six years, committing over $41.5 billion in headline deal values while managing to produce a paltry $18.6 billion in actual FDA-approved assets. The rest was a graveyard of ambition, a fiscal wasteland where shareholder capital went to die.
I lived through the autopsy of those deals in real-time. I watched Receptos, a wholly-owned subsidiary of Celgene acquisition: a staggering $7.2 billion bet—produce the humiliating, catastrophic FDA Refusal-to-File disaster for what was then known as ozanimod, a debacle that signaled to the entire Street that our regulatory intelligence was asleep at the wheel. I watched the $1.1 billion upfront poured into Impact Biomedicines shrivel into a ghost town as Inrebic choked on a black-box warning and crashed against the hard rocks of commercial reality. I watched the $710 million Nogra partnership for Mongersen implode in Phase III trials, turning a supposed savior compound into expensive medical waste. The OncoMed partnership at $3.3 billion cratered; the Jounce deal evaporated into thin air; Prothena, Forma, Acetylon—they all vanished like morning mist under the harsh sun of clinical failure.
Celgene had stopped playing the long, disciplined game of organic scientific discovery. It had devolved into a corporate empire trying to brute-force innovation through checkbook diplomacy, throwing billions of dollars at unproven platforms simply to generate press releases that would keep the stock price stable for one more quarter. It wasn’t strategy; it was a coping mechanism. It was management hiding under the bed covers, praying that the bogeyman of the Revlimid patent expiration would magically go away if they bought enough shiny biotech toys.
And in 2018, the bill finally came due on Celgene's down payment with sudden hidden interest.
The executives from Bristol Myers Squibb didn’t even try to hide their astonishment and quiet fury as they peeled back the hood during the Acquisition Due Diligence (ADD... not the AuDHD & CTE that I Got ;). They had agreed to shell out $74 billion for an enterprise built entirely on a decaying foundation, only to discover that our panic-driven shopping spree had saddled them with billions of dollars in high-priced, underperforming baggage. The infamous CVR—the Contingent Value Right designed as a clever financial parachute—was already being eyed by Wall Street sharpshooters as an unpayable gamble, destined for the executioner's block to save BMS $6.4 billion. The then pipeline drug known as Breyanzi® (lisocabtagene maraleucel) HCP had manufacturing deadlines which were slipping into manufacturing purgatory. The early-stage pipeline was a smoking ruin; the late-stage pipeline was wheezing under the strain.
Celgene was being sold. Celgene was being absorbed. Celgene was being digested and erased from the corporate map. And as I sat at my desk watching the empire fold in upon itself, a strange, luminous peace washed over me.
For the first time in my life, I realized something simple, terrifying, and completely liberating: I no longer mattered.
This wasn't the nihilism of a beaten man, nor was it the cynical detachment of a corporate casualty. It was something entirely different—it was the exact spiritual awakening Jon had tried to hand me without ever opening his mouth. When you are staring down the barrel of fatherhood while your brother lies six feet under and the company that defined your adult life dissolves into a merger-and-acquisition footnote... your career as you knew it dies a painless and permanent death, aside from what you and your colleagues remember and your resume. Your frantic ambitions quiet down. Your desperate need to control the narrative evaporates. Your identity shifts away from your title, your salary, and your stock options (non-qualified or otherwise), anchoring itself entirely into the lives of those who come after you. Stacy was carrying our child. Jon was gone. Celgene was vanishing. And Elliott was on his way down the track.
What follows a realization like that is not passivity; it is clarity. With my personal vanity stripped away, I moved through the rest of 2018 with absolute, ice-water-in-the-veins focus. I settled the scores that needed settling—the professional and personal debts that had lingered too long in the shadows, requiring closure before a new era could begin. I protected the loyal people who deserved protection from the incoming corporate bloodbath, and I ruthlessly cut loose the false friends who just wanted boring money.
I invested prudently and saved aggressively because a parent does not have the luxury of financial recklessness when mouths are waiting to be fed. I took care of the new house from top to bottom, getting things set up as best I could—CTE and all—because a child was coming and his nursery—and Stacy's Nest, as my Rugby Playing buddy Matt Hagan once put it (Matt never met Stacy but he is a Christian and father of three who plays rugby and turned Istodax around - with my and CELG's deep influence - in 2014)—had to be a fortress against the cold world. I walked Ainsley four miles every single day through the crisp autumn leaves of Basking Ridge because the dog didn't care about stock prices or corporate buyouts; he only cared about the rhythm of the leash and the sound of my voice. And mostly, I waited.
When Evvy, our little Eliotte, was finally born, the universe clicked into its proper alignment.
He came into the world with blue eyes that stopped me dead in my tracks—the exact, unmistakable eyes of my brother Jon... it still inspires me when he looks at me and tells me how it is, just like Jon did. My baby's eyes are calm, honest, steady, and terrifyingly observant. When he opened them and looked at me eventually, he didn't look like a screaming infant; he looked like an old soul checking to see if I was finally paying attention. He looked at the chaos of the world the way Jon had always looked at it: with deep, unshakeable curiosity instead of reactive fear, with gentle grace instead of desperate ego, with absolute clarity instead of corporate static.
And then, as the years rolled forward, came Logan-San —the second son, the chaos twin (the Thor to Eliot's Loki... much like Jon was Loki to me, and Sean was too... until we lost Sean decades before Charlotte was born), the fierce little bolt of lightning who carries my own fire, my stubborn humor, my relentless intensity, and my unyielding spark. Erverette... I mean Eliot! is Jon’s living legacy, carrying forward the steady, noble engine of a gentle, brilliant soul who left us all too soon. Logan is my little shadow, testing every boundary and forcing me to confront every flaw in my own nature. Charlie remains the beautiful, shining bridge between these two distinct worlds, holding our extended family together with the fierce love her father instilled in her. I hear she is doing well. I pray for all my kids, every day, just like Grandpa Andy taught me to.
That is how 2018 ends in the true ledger of my life. It does not end with Celgene’s $74 billion buyout announcement. It does not end with the pathetic wreckage of Celgene's mostly failed BD deals or the multi-billion-dollar write-downs. It does not end with the sharks circling Summit, the stock tickers flashing red, or the toxic culture of a dying corporate giant.
This chapter ends with a birth far more important than my own. It had started tragically with Jon's death. Thus, the CE year of 2018 continued with a brutal, beautiful paradigm shift.
Jon left this world so that we could learn how to truly inhabit it without the smartest person I ever met... the big brother I needed for my Electric quantum magnetism (my EQM), if you will. Elliot entered it to show me what actually matters. And I—the man forged in the fires of Celgene’s golden age, broken by grief, schooled by brilliant mentors, hardened by corporate betrayal, and saved by faith and fatherhood—finally understood the foundational secret of existence:
You no longer matter. Your children do. And that realization is the beginning of everything.
EPILOGUE: The Commercial Physics of Oncology and Celgene Gravity (2022+ C.E. (Common Era... or, my Children's Era ;D)
American healthcare is not just any system. It is the largest employer in the world and dictates much of our global health despite our country representing only ~5% of the Earth’s current population.
American healthcare is one massive Quantum Physics experiment that plays out in Real Time.
Every incentive, every price, every executive decision, every acquisition, every failed trial, every miracle therapy, every patient victory, every patient death—all of it moves according to forces that most people never see.
They see the headlines. They feel the copays and they see the bills.
They see the DTC commercials and see the smiling physicians in brochures.
They see the ground-breaking and ribbon-cutting ceremonies.
They hear about the approvals and wait for life-saving pills.
But they never see the engine or appreciate it. I Helped Build the Engine. Vroom, vroom!
For a number of years, I went to work and sat inside one of the most profitable oncology machines in human history—a converted middle school that became a $100 billion titan. I watched it rise. I watched it rot. I watched it get swallowed whole. I watched it get erased. And I watched what it cost.
Not in dollars.
In People. Patients. Families. Field teams. Analysts. Scientists. Executives. Children. My own.
The physics of American healthcare are simple, brutal, and mathematically consistent:
● If a therapy works well, the Price Rises Quickly.
● If a clinical trial fails to meet its primary endpoint… the Price Still Rises.
● If a company succeeds, the Price Rises.
● If a company collapses, the Price Rises One Last Time… in a pathetic, desperate move.
The patient, insurer, and taxpayer always pay. The system rarely does.
We built an oncology empire on the back of an old, defeated drug called thalidomide (Old Uncle Thal, as Bob McMahon once called it before he left for Incyte in 2012). We built quarterly forecasts on the cadence of their refills. We built revenue projections on the length of their survival curves. We built entire careers on the hope that their disease would respond for one more month, one more cycle, one more line of therapy.
And when the patent cliffs came—when the physics shifted—we didn’t slow down.
We sped up.
We bought expensive pipelines which we didn’t fully understand and platforms that we couldn’t yet validate. We bought hope at a premium… and eventually sold it to BMS at a discount. We bought time we didn’t have, and pretended this was a strategy.
We called it innovation. Wall Street called it growth. Patients called it survival.
But it was something else entirely. It was Blood Money.
Not because the people were evil. Most weren’t. Most were brilliant, disciplined, compassionate, exhausted, and trying to do the right thing inside a machine that rewarded the wrong things.
But the incentives were stronger than the intentions. In American healthcare, incentives always win.
You can have the best scientists in the world. You can have the most disciplined executives. You can have the most dedicated field force. You can have the most courageous patients.
But if the incentives are misaligned, the outcomes will be too. And they are still grossly misaligned in America.
We spend more per capita on healthcare than any nation in human history. We achieve outcomes that rank below countries with a fraction of our resources.
We reward financial engineering more than biological engineering. We reward acquisitions more than discoveries.
We reward quarterly beats more than long-term cures. We reward noise more than truth.
The physics are wrong. So the results are wrong. And patients suffer the results, not the cost or the lack of Critical Thinking that our American Government currently possesses.
And the bill is coming due. Not just for me, and certainly not for Celgene now that it’s gone. Not for Big Pharma, and never for Wall Street.
Not for the executives who cashed out and retired with their golden parachute. Not for the analysts who built the dashboards. Not for the consultants who wrote the decks.
The Bill will be Coming Due for our Children.
ALL OF OUR KIDS. These are children who will inherit a system that was built to extract rather than heal, to optimize dollar spend rather than cure, to sustain rather than solve.
The Ghosts on my Ledger (Survivor’s Shame more so than guilt)
People talk about trauma like it’s a car crash—sudden, violent, deafening, and over in seconds. But survivor’s guilt isn't a crash. It’s a slow-leak carbon monoxide detector that you can't shut off.
When the dust settled on Celgene, when the $74 billion merger closed, when the court dates passed, and when the quiet finally returned to our house in Basking Ridge, I was left with the hardest question of all: Why me?
Why did I get to walk out of the Cauldron with my mind intact, my family whole, and a second chance at building something better... while the people who carried more grace, more talent, and more light than I ever possessed didn’t make it across the finish line?
I miss Jon. The brilliant, gentle engineer from New Providence who saw the equations of the universe with crystal clarity, who loved his child Charly with his whole soul, and whose empty chair still echoes in our family.
I miss Sean. My big brother, the sales engineer, the skateboarder, the comedian, the guy who shared my blood and my random roots, whose tragic, senseless murder in an Ohio motel room left a jagged hole in my family history… which no corporate success could ever fill.
I miss Mark Smedstad. A pillar of brilliance and institutional memory who gave so much of his life to the Twin Groves Junior High and Purdue University grind, only to become an Angel before he enjoyed the fruits of his labor.
I miss Cecil Fonseca IV. My best friend at Celgene, a kind soul, a wonderful father whose son Jayden looked at me and said, "I want to be like Big Jeff." Returning to the office after the lockdowns and seeing his cube empty, his personal things still sitting there waiting for a family that didn't know… that image still breaks my heart.
And I miss Uncle Earl. Another guiding light from the older generation who taught me what steady, quiet strength looked like before the world got so loud. He fought pancreatic cancer off for almost 5 years. A Vietnam vet, like my biological father.
I carry them. I sit at a desk, I write my code, I look at my two kids —Eliot and Logan—laughing in the backyard, and a sudden, sharp wave of guilt
hits my chest. I always wonder if I did enough.
You wonder if you could have picked up the phone, or driven out to Ohio or Illinois, or spotted more warning signs, or pulled them out of the fire. You’ll always wonder. That sense of Wonder never goes away… for better or worse.
The brutal truth of Survivor’s Shame is that it tries to convince you that your survival is An Accident… or a Betrayal.
It took me years of therapy, years of faith, and years of holding my kids close to realize that guilt is just grief that doesn't have an address, except for in one’s mind.
They didn't lose their lives so you could spend the rest of yours drowning in remorse. They lived, they loved, they fought, and they left us chapters short of the ending they deserved.
The only way to honor ghosts like Jon, Sean, Mark, Cecil, and Uncle Earl is to Build Something Better with the breath that I have still got. To Tell the Truth. To protect the people on the front lines. To build companies that don't crush human beings for a quarterly beat. To be the father they would have been proud of.
I built the data engines. I survived the corporate autopsy. When I am alone, and not with my kids… I Live with Ghosts. Hotel del Coronado was real to me. I believe in the afterlife… whatever form it takes.
And every single day I wake up, I try to make sure the time I bought with my survival is actually worth what it cost them.
The True Lessons of “Blood Money”
Now as I finish my first book in October of 2026—over 15 years since I first stepped foot in Summit, New Jersey—a friend asked how I categorize my first book, Blood Money. It is five things at once, if not moreso. A Truly Quantum History of Celgene Biopharma and thus the past 16 years of Cancer Care... or so.
If you want to understand how this industry actually works, you look at the people. You look at their results.
If you follow the tracks of the true elite, you start with Shawn Tomasello—the "Dragon Queen from Ohio." When Shawn left Celgene, she went to Pharmacyclics to lead a new blood cancer company, and they were promptly bought by AbbVie for $21 billion. Then she went to Kite Pharma, and they were bought by Gilead for $11.9 billion. People in the know understood a fundamental law of biopharma: if you tracked Shawn's moves... it was Ohio Blue Collar Biopharma $$$
Even veterans like my friend Brendan Delaney—who put up legendary numbers at Novartis, Celgene, and Immunomedics (driving the Trodelvy launch before its massive $21 billion acquisition by Gilead)—knew that elite tier. I think that Brendan now runs a farm with his family and sounds like a Happy Camper.
Then there are leaders like Nadim Ahmed at Culligan (CGEM), representing a deeply respected archetype: a man who didn't build a company just to flip it, but rather wanted to lead it, grow it, and anchor a Culture of Kindness with genuine integrity and humanity. Nadim could retire if he wanted to, but he chose to lead another company.
And on the political and executive coin, figures like Bob "TEH Huggy Bear" Hugin steered the ship through massive growth, proving that even the most formidable biopharma titans operate under complex constraints when they step outside their home territory.
That is the reality of the game. It’s built on scientific data, financial investments, SQL queries, and market access contracts—but at its core, it's driven by human patients.
And what about me, Jeff Conroy? Well… I finally caught COVID-19 in January 2022, just days after receiving my booster shot. Sick, exhausted, and staring at the ceiling, right before I resigned from BMS. Not because I didn’t respect the people—I did—but because I needed a New Challenge and a New Biotech Company to mold, and I found one.
BMS (SS: BMY) acquired several more oncology companies after Celgene. Some integrations worked. Some did not. And then came the reports of a potential megamerger with AstraZeneca in August 2026—a deal so unimaginative and structurally bloated that it would almost certainly be capital and career destructive. Another attempt to brute-force a golden era through scale instead of culture, discipline, and truth.
We have seen this movie before. Do they think we forget so quickly?
Yet the leaked reports of a potential megamerger with AstraZeneca (SS: AZ) prove that the old guard hasn't learned a damn thing. It is another attempt to brute-force a golden era through scale and paper-shuffling instead of culture, discipline, and truth.
I had seen this movie before. Do they think we forget so easily?
Celgene was not perfect, but it was a cancer-fighting community at its peak. When it rotted, it rotted from within—not because the science failed, but because the culture cracked, the incentives warped, and leadership traded operational rigor for financial engineering and splashy BD deals.
Those hard-earned lessons are why I founded Global HC Analytics and why Catalyst Oncolytics Corporation is being engineered from the ground up to operate differently: fewer layers, cleaner AI-driven Python models, absolute transparency on Access, and Zero
reliance on corporate panic. It is a Private Company for a reason.
We have the talent, the data, and the capital in America to build a better system. What we need is the courage to admit that the Old Machine is Broken—and the discipline to stop repeating the same old mistakes.
I saw the old engine and helped build the Current AI-driven Commercial Engine (Biopharma is full of copycats - but Imitation is the Highest Form of Flattery, is it not? ANYONE can do what I have done… just Work Hard and Do the Next Right Thing and Stay Focused on Your Most Important Goals).
I understood the physics of Celgene’s gravity from 2011 until we were acquired in 2019, and I felt the cost.
The Celgene Corporation was a grand experiment—one that shaped an entire generation of biopharma development and corporate leaders. If you worked at Celgene, then you learned lessons you carry for life. Even if you’re a fat old middle aged white guy now, like Brad, Craig, Eddie, Steve, and I all are these days.
How do we shatter the glass ceiling for women and minorities? Look to all the ones who worked at Celgene; some have become CEOs, and everyone who survived a year there can run their own company.
These lessons informed my decision to leave BMS in late 2021 despite family difficulties. They helped me found Global HC Analytics LLC in June 2024.
They led me to write "Blood Money" in secret, On and Off for Fun like a Binary Bit, for the past two years. As you know I am clearly a biological male but I identify as Nonbinary because Fatherhood has Taught me that We are All Nonbinary at Conception, whether You Like that Fact... or not. ;)
Because the American Healthcare Industrial Complex needs to hear the truth. And everyone deserves to know.
Less is often more. And in the AI era, you can do more with less—if you have discipline, clarity, and courage. The Catalyst Oncolytics Corporation model is being built on those principles.
I hope this book helps provide a record of why ethics and principles matter in oncology companies, in healthcare, and in all life. This is neither corporate PR nor sanitized history. This is the version I lived through—the Celgene that helped me grow, helped me when I was broke personally (never professionally), and ultimately pushed me to build something better.
And somewhere along the way—through the rise, the rot, the grief, the rebuilding, the fatherhood, the therapy, the reinvention—I finally learned more truths about myself, too.
I was not 100% certain that I am autistic until I was diagnosed a few years ago. I didn’t know the intensity, the pattern recognition, the emotional clarity, the hyperfocus, the memory, the honesty—all the things that shaped my career and my life—had names. Autism. ADHD. Depression. Neurodivergence.
These aren’t weaknesses and they were not caused by vaccines. They’re the architecture of my mind. They’re the reason I could build engines inside Celgene that nobody else could build.
My unique brain structure is likely the reason I am able process everything - eventually - and is the reason why I keep surviving things that would break some. My neurodivergence is the reason I could rebuild myself as a father, a husband, a company founder… and now, I suppose, as a long-form writer.
They also explain why I’ve been misunderstood, underestimated, and often targeted by people who don’t know what to do with someone who refuses to lie, refuses to play games, refuses to hide, refuses to bend. Neurodivergence didn’t make me vulnerable—it made me visible. I am proud to be neurodiverse. And I think you should be, too.
Because everything I lived through—the corporate rise, the collapse, the grief, the reinvention, the fatherhood, the trauma, the clarity—all of it became the only thing it could become: a story. A record. A reckoning. A blueprint. A warning. A testament.
I wrote this book because I want my children to live in a country where healthcare is not a physics experiment—but a promise.
● A promise that if you get sick, the System will Help You.
● A promise that if you need treatment, you won’t go Bankrupt.
● A promise that if a therapy Works, it will be Accessible.
The Promise that if a company succeeds...
then Patients Succeed too.
The Promise that Innovation is measured in Lives Saved, not Financial Quarters Beaten.
We can build that system. We have the talent. We have both science and technology on our side now. We have the data. We have plenty of money in America.
We always have the need. As Celgene’s Legendary Chief Medical Officer Jerome Zeldis once said: “Patients are Waiting.”
What we lack is the courage to admit the truth: The system is not broken. It is working exactly as designed. THE INCENTIVES of our American Healthcare is the Problem.
I saw the engine, I understood the physics, and I felt the cost. And now you have, too.
Look away if you prefer to do so. That is your God‑granted American right.
But this, my World Wide Web of Internet Colleagues, Friends, and Strangers... is how BLOOD MONEY made.
My Global Network Friends and Neighbors or Enemies...
this is how Blood Money gets made.
...
APPENDIX A - The Celgene Deals from 2012 to 2018: What BMS Actually Bought
Between 2012 and 2018, Celgene ran what was perhaps the most aggressive business development engine in modern biotech. It was fast, expensive, and relentless — almost $23 Billion in upfront capital and $42 Billion in headline commitments poured into acquisitions, collaborations, and option deals.
When you line up every transaction, the pattern becomes unmistakable: a handful of genuine wins surrounded by a long wake of failures, write‑downs, and scientific dead ends. This appendix is not about blame. It’s about accuracy — the historical record of what Celgene built, what it bought, and what Bristol Myers Squibb ultimately acquired in 2019
.
The spree began in 2012 with a cluster of high‑conviction bets on emerging platforms. Celgene acquired Avila Therapeutics for nearly $400 million in cash plus equity, aiming to build a covalent inhibitor franchise around Btk and EGFR. The programs failed in Phase I/II, unable to match Imbruvica’s clinical profile, and were terminated.
The same year, Celgene paid $90 million to Epizyme for EZH2 methyltransferase inhibitors; the programs stalled in Phase II. Acetylon’s selective HDAC6/HDAC1/2 inhibitors showed no meaningful synergy in multiple myeloma. Quanticel, acquired for $100 million, delivered a single‑cell genomics platform that never produced a clinical asset. Four deals, nearly $700 million in upfront
capital — and not a single FDA approved drug as a result.
In 2013, Celgene doubled down. The OncoMed collaboration — $155 million upfront and a $3.3 billion headline — centered on anti‑CSC antibodies like demcizumab. The program failed Phase II in pancreatic cancer and NSCLC for toxicity and lack of efficacy. Forma Therapeutics delivered broad discovery work but no clinical programs. Abide Therapeutics’ serine hydrolase inhibitors died in Phase I.
Nogra Pharma’s mongersen (GED‑0301), licensed for $710 million, became one of the decade’s most disappointing clinical failures when the Phase 3 RESOLVE trial collapsed. Mongersen was one of the few competitive bids Celgene ever won — five companies pursued it — but the price did not change the outcome.
One deal in 2013 did work: the Bluebird Bio collaboration. Celgene paid $225 million to enter the BCMA CAR‑T race early, and the partnership produced Abecma, an FDA‑approved therapy for multiple myeloma. It remains one of the few successes in the ledger.
The pattern continued in 2014. Sutro Biopharma’s cell‑free ADC platform stalled in early clinical development. Phoenix PharmaLabs’ opioid candidates failed preclinically. Forma’s second alliance produced no clinical assets.
But one deal stood out: the for Acceleron’s luspatercept. Celgene paid $25 million upfront for a recombinant fusion protein targeting TGF‑beta ligand traps. The program became Reblozyl (TM, Trademarked now by BMY... naturally), a blockbuster with more than $2.3 billion in peak sales — the crown jewel of Celgene’s BD (Bad Deal) era.
By 2015, the biopharma industry was still reverberating from Gilead Sciences's success with Sovaldi. The $11 billion Pharmasset acquisition in 2011 had become one of the most profitable drug deals in history, effectively wiping out Hepatitis C and generating tens of billions in revenue.
Between 2014 and 2016, Sovaldi and Harvoni dominated headlines and earnings calls. Every BD team — Celgene included — felt the pressure. Everyone wanted “the next Sovaldi,” the next transformative asset. That psychology inflated valuations and fueled aggressive bidding.
The Receptos deal was signed in that environment, especially after mongersen failed and Celgene needed another product to pair with Otezla to grow the Inflammation & Immunology (I&I) portfolio.
Then came 2015 — the year of massive bets. Celgene acquired Receptos, a wholly-owned subsidiary of Celgene for $7.2 billion, aiming to secure a long‑term immunology franchise with ozanimod. The drug eventually reached approval, but only after an FDA Refusal‑to‑File letter in 2018 and years of delay. Commercial performance never justified the price.
The initial Juno collaboration — a $1 billion equity and option deal — served as Celgene’s entry into CAR‑T (along with the earlier bluebird bio deall) and paved the way for the later $9 billion acquisition. Celgene also paid $2 billion to secure PD‑1 combination access with Bristol
Myers Squibb, enabling critical Revlimid and Pomalyst trials. Agios delivered two approved IDH inhibitors, Idhifa and Tibsovo — scientifically validated, modest commercially.
Celgene's investments in Cell Therapy, specifically CAR-T (chimeric antigen T-Cell receptor therapies) and bispecific antibodies and Gilead's acquisition of Kite Pharma accelerated the field significantly, and this investment in science to benefit blood cancer patients cannot be ignored. The failures continued. Triplet Therapeutics’ early antisense and RNAi programs never reached clinical entry. Jounce Therapeutics’ ICOS agonist failed Phase II. Anokion’s immune tolerance platform died in Phase I. Evotec’s iPSC‑derived neurodegeneration programs produced no candidates. Vividion’s chemoproteomics platform was validated scientifically: Bayer later acquired the company for $1.5 billion — but Celgene saw no direct drug revenue.
By 2017, the pattern was unmistakable. Delinia’s engineered IL‑2 muteins failed in early trials. Evotec’s second alliance produced no assets. Triplet’s second collaboration collapsed. These were not isolated misses — they were systemic. The BD engine was running hot, but the output was consistently cold.
And then came 2018, the final year of the spree before Celgene was acquired by BMS. Celgene acquired Impact Biomedicines for $1.1 billion upfront, betting on fedratinib (Inrebic), a JAK2 inhibitor for myelofibrosis — a deal that surprised those who knew the space. Inrebic eventually received FDA approval but carried a Black‑box warning for encephalopathy and was commercially crushed by Jakafi, generating less than $100 million in peak sales
The $9 billion Juno acquisition produced Breyanzi, now a $1.4 billion CAR‑T therapy — but only after Bristol Myers Squibb resolved major manufacturing concerns. The Prothena neurodegeneration alliance stalled entirely.
Across the entire ledger, only four deals produced FDA‑approved drugs: Abecma, Reblozyl, Breyanzi, and Zeposia — and Zeposia has underperformed its $7.2 billion price tag as of October 2026. Everything else was written down, terminated, or quietly absorbed.
Celgene’s BD engine was a high‑velocity, high‑spend, high‑attrition machine. It produced a few genuine wins — and a decade of puzzling head‑scratchers. When Bristol Myers Squibb acquired Celgene in 2019 for $74 billion plus a $6.4 billion Contingent Value Right (a CVR), the structure wasn’t a mystery — it was a choice by both companies.
According to the U.S. Securities and Exchange Commission documents released in 2019, BMS had offered Celgene an additional $1 or $2 billion in cash to close the deal cleanly.
But Celgene’s leadership insisted on the CVR instead. It was a(NOTHER) fatal miscalculation — a bet on regulatory timing that ignored basic probability, operational risk, and the realities of FDA manufacturing inspections.
BMS acquired the late‑stage assets: Reblozyl, Breyanzi, Abecma, Zeposia, and Inrebic. They did not only acquire the early pipeline. They acquired the revenue engines and the salvageable programs.
The CVR included a milestone tied to the FDA approval timing of lisocabtagene maraleucel (Breyanzi). That milestone required approval by a specific contractual deadline. Due to manufacturing delays — including issues at the contracted Lonza facility and subsequent testing and remediation work — Breyanzi’s approval came 36 days after the CVR deadline.
Under the terms of the agreement, missing that date meant the $9‑per‑share payout (approximately $6.4 billion) was not triggered. Courts later dismissed shareholder claims, affirming that the CVR operated exactly as written.
BMS conducted its own post‑acquisition portfolio reviews as is to be expected. Inrebic, acquired through the $1.1 billion Impact Biomedicines deal, underwent significant intangible asset adjustments following its Black‑box warning and limited commercial performance. Zeposia, acquired through the $7.2 billion Receptos deal, also required multi‑billion‑dollar intangible value adjustments to reflect its real‑world trajectory. And dozens of early‑stage alliances — OncoMed, Jounce, Prothena, Forma, Acetylon — were discontinued or allowed to lapse, with their upfront payments absorbed as sunk cost.
But BMY did what Big Pharma does well: they further developed the winners. Reblozyl became a blockbuster. Breyanzi overcame manufacturing bottlenecks. Abecma found its footing. The rest were quietly retired.
Appendix A of my first book, "BloMoney" is the ledger — the seven years of clinical‑stage deals that absorbed Celgene’s balance sheet, led to its pipeline, and its fate.
APPENDIX D - The Lazorchak Indictment in 2012: Governance Failure, Cultural Farce, and the Legal Reset for Celgene’s Golden Era (2012)
I. Overview: What Happened and When We Found Out from the Company
In 2012 C.E., federal prosecutors charged John Lazorchak, Celgene Corporation’s Director of Financial Reporting, with insider trading and tipping confidential financial data to non‑employees. Their Operation was amateurish, short‑lived, and detected almost immediately by automated regulatory surveillance systems. Upon learning of the federal investigation, Celgene terminated Lazorchak without hesitation and cooperated fully with authorities.
Within the broader context of Celgene’s disciplined Golden Era, the incident stands out as a stark governance anomaly — a moment that reminded every Celgene employee that the company’s culture under CEO Bob “Huggy Bear” Hugin had evolved into a Zero‑Tolerance Compliance Regime. The Golden Era was disciplined; this was the moment it became formally disciplined.
This appendix summarizes the public record, analyzes the structural vulnerabilities exposed, and situates the event within New Jersey’s biopharma ecosystem.
II. Role and Access
Lazorchak occupied a sensitive position granting visibility into:
* confidential quarterly earnings
* revenue projections
* drug‑approval timelines
* internal performance metrics
* financial reporting documents
He held no responsibility for R&D, clinical development, or scientific operations. His risk profile stemmed entirely from high‑information access rather than operational influence.
From a governance standpoint, he sat squarely in a “high‑information, low‑visibility” zone — the precise structural vector demanding rigorous, multi‑layered internal controls.
III. The Scheme (Public‑Domain Summary FREE OF CHARGE on https://theghca.com )
According to U.S. Department of Justice and SEC filings, Lazorchak:
* tipped friends and associates with material non‑public Celgene financial metrics
* leaked advance knowledge of quarterly earnings and regulatory milestones
* routed trades through secondary accounts in a crude attempt to mask ownership
* participated in an insular cluster of individuals who executed the trades
Regulators described the scheme as brief, unsophisticated, poorly concealed, easily traceable, and rapidly dismantled. Trading patterns were so obvious that automated surveillance systems flagged them almost immediately.
The group’s behavior resembled cultural caricature — more suburban roleplay than criminal sophistication, evoking the tone of a “HBO Sopranos- Boss Tony Soprano and Paulie Walnuts wannabe types” imitation rather than Wall Street white‑collar crime.
IV. The Cultural Farce
Although the legal consequences were severe, the operational conduct bordered on absurd. The participants demonstrated little competence at criminal matters. They showed:
- careless communication habits
- predictable timing
- no operational security and no staggered execution
- no attempt to mask relationships
- Literally zero understanding of surveillance algorithms
Rather than a calculated conspiracy, the group behaved like hobbyists imitating cinematic mob tropes — a low‑budget parody of organized crime. This assessment is not speculative; it is the logical conclusion drawn from the DOJ’s own description of the scheme’s transparency.
V. Enforcement and Aftermath
The response was swift:
- The Federal SEC's Surveillance Algorithm flagged abnormal trading behavior
- DOJ initiated a formal investigation
- Arrests and indictments followed
- Celgene terminated Lazorchak immediately
Celgene’s leadership cooperated fully with federal authorities, drawing a bright line between corporate integrity and individual misconduct. Lazorchak faced the legal consequences without institutional support.
VI. Governance Significance
The incident punctured the illusion of corporate invulnerability during Celgene’s hyper‑growth era. It exposed:
Gaps in access control
- Vulnerabilities in financial reporting oversight
- Blind spots in mid‑level insider‑threat management
- Limits of trust‑based governance models
- The reality that high‑performing organizations remain vulnerable to human weakness
For a company known for precision and discipline, the episode underscored that governance is fundamentally behavioral, not merely structural.
VII. New Jersey Biopharma Ecosystem Context
New Jersey’s biopharma corridor is not merely a geographic cluster; it is a corporate ecosystem with its own behavioral physics. The region’s pharmaceutical identity has been shaped by legacy giants, sprawling campuses, dense professional networks, and a regulatory presence that is both constant and unforgiving.
A. Corporate Geography: The Campus Culture
New Jersey’s pharmaceutical landscape is defined by a few things such as multi‑building campuses, thousands of employees in close proximity, overlapping professional circles, and informal networks that span companies and towns.
Physical density creates information density… and this Information density creates Risk Density (the Physics of Compliance...
the sequel to Blood Money, DUMBER Money, about the NCAA and Title IX... Coming soon!)
B. Legacy Pharma Culture: The Old Guard Meets the New Guard
The corridor is home to Merck, J&J, BMS, Novartis, Sanofi, and Celgene — creating a legacy culture built on:
- institutional memory
- tribal knowledge
- reputational gravity
- The “Unwritten Rules” of biopharma
This culture accelerates execution — and accelerates exposure.
C. Tight‑Knit Networks: Human Vectors of Risk (the Same Way the COVID-19 Pandemic Spread like Wild Fire)
Professionals in the corridor: live in the same towns, attend the same gyms, frequent the same diners , and rotate through the same companies - so there is Material Risk all over the industry.
This creates high‑velocity information flow — a high‑trust, high‑risk environment where trust accelerates collaboration and leakage simultaneously.
D. Regulatory Presence: The Constant Shadow
New Jersey sits under: SEC surveillance, constant DOJ scrutiny, FDA proximity, and Wall Street attention.
Abnormal trades are flagged instantly. Insider networks collapse quickly. Compliance failures become public fast.
E. The AI Era: Surveillance at Scale
By 2012, surveillance algorithms were already sophisticated. In 2026, they are relentless.
Artificial intelligence has transformed: market surveillance and insider threats anomaly detection.
In New Jersey’s corridor, AI doesn’t just watch — it anticipates.
F. Lessons of the Corridor
The Lazorchak case distilled four truths:
A. Access equates to Organizational Power ... or "Influence", as the kids call it these days
B. Power requires strict Oversight - WHO WATCHES THE WATCHMEN, HBO... eh?
C. Oversight demands constant vigilance
D. Vigilance is driven by Your Company Culture
G. Why This Matters for Blood Money and other Companies Moving Forward
Celgene’s Golden Era did not exist in a vacuum. It existed in New Jersey — a place where Information moves fAst, Regulators move Faster, and Governance Failures are exposed with Brutal efficiency.
VIII. Conclusion
The Lazorchak incident was not a systemic failure; it was a localized human Mistake — brief, contained, and decisively pruned. Yet it deserves documentation because it reveals the fragile seams of governance during Celgene’s ascent and illustrates why internal controls are non‑negotiable at scale.
Within “Blood Money” and my personal career journey: it marks the moment when the Golden Era’s polish briefly dimmed, exposing the imperfect human reality behind the corporate facade.
For the record: I never met Mr. Lazorchak and bear him no personal animus. The incident changed Celgene (CELG) — and by extension, New Jersey and American biopharma (BMY, GILD, ABBV). Mr. Lazorchak pled guilty, served the Time, and has Moved On with his life. I hope he is doing well. I and many other biopharma employees learned from his mistake... and, given I have been arrested as well... and I certainly know we all make mistakes.
APPENDIX X — CASE STUDY: A Benefits Allegation & Third-Party Oversight Investigation
Course Designation: Executive MBA / Law School / Graduate Corporate Governance & Business Ethics
Topic: Corporate Governance, Third-Party Vendor Risk, Internal Investigations, and Structural Oversight Limits
Abstract
This case study explores the ethical, operational, and governance dilemmas that arise when serious allegations of misconduct involve third-party vendors who lie outside an organization’s direct investigative reach. Set against the backdrop of a high-growth, highly regulated biopharmaceutical firm under intense commercial and financial pressure, this case examines how internal rumors, high-stakes executive investigations, and structural limitations in vendor oversight can create severe operational volatility—even when allegations remain unproven.
I. Learning Objectives
By analyzing this case study, students will be able to:
- Evaluate Structural Limits in Internal Investigations: Analyze why standard corporate compliance frameworks struggle when external third parties decline or refuse full cooperation during internal reviews.
- 2. Assess the Cultural & Operational Cost of Unresolved Allegations: Understand how unverified rumors and high-stakes internal probes can induce organizational anxiety, leadership friction, and operational distraction.
- 3. Design Comprehensive Third-Party Oversight Frameworks: Formulate vendor risk-management controls—such as mandatory audit rights, transparent ownership disclosures, and strict anti-bribery/perk policies—to prevent governance blind spots.
II. Background & Context
In late 2018 or mid-2019, a mid-sized global biopharmaceutical enterprise was navigating a pivotal transition marked by clinical pipeline setbacks, heightened drug-pricing scrutiny, and impending strategic shifts. Within the commercial operations division, rumor and internal reporting alleged that four senior commercial executives had engaged in an improper financial relationship with a key third-party data vendor.
Specifically, allegations circulated that a contract for several hundred thousand dollars (a large financial commitment to obtain data) tied to the vendor relationship via a contract was accompanied by unmonitored hospitality benefits, high-end recreational trips, and informal perks such as Golf Trips and Whiskey Tasting Sessions.
The Enterprise’s Leadership recognized the immediate severity of the claims:
- Regulatory Exposure: In a heavily audited healthcare sector, any undisclosed financial intermingling between corporate decision-makers and commercial vendors raises severe compliance and fiduciary issues.
- Organizational Stability: Coming at a moment of broader corporate vulnerability, a substantiated executive-level ethics scandal risked destabilizing ongoing strategic initiatives and damaging stakeholder trust.
III. The Investigation and the Wall of External Non-Cooperation
Corporate compliance and legal counsel initiated a formal internal investigation to determine the veracity of the claims. The inquiry created substantial tension across the commercial leadership hierarchy, accompanied by heightened anxiety and interpersonal friction within executive suites.
However, the investigative team quickly encountered a critical structural barrier: the limits of internal jurisdiction.
1. Lack of Compulsory External Process: While the company could review internal emails, corporate expenses, and internal database logs, it lacked subpoena power or legal mechanisms to compel internal financial records, communications, or testimony from the independent third-party vendor.
2. Vendor Non-Cooperation: The third-party vendor refused voluntary disclosure of its internal books, equity tables, or hospitality records.
3. Absence of Conclusive Evidence: Without access to external financial trails or third-party documentation, investigators could neither corroborate nor definitively disprove the allegations. A "Brick Wall".
Because the "smoking gun" required to substantiate the claims could not be obtained, the investigation reached a standstill. No formal charges or administrative discipline could be levied against the executives. The matter concluded without headlines or public disclosures, leaving behind an unsubstantiated file and lingering questions regarding systemic exposure.
IV. Key Ethical & Governance Takeaways
1. The Distinction Between "Absence of Evidence" and "Absence of Risk"
In corporate compliance, the inability to prove an allegation due to jurisdictional boundaries does not guarantee the absence of underlying operational risk. Organizations must recognize that structural blind spots in vendor relationships can leave an enterprise vulnerable to reputational harm even when formal wrongdoing is unproven.
2. The Organizational Toll of Governance Fragility
High-stakes internal investigations into senior leadership inevitably consume bandwidth, increase executive stress, and disrupt focus. When compliance infrastructure relies primarily on internal goodwill and employee trust rather than enforceable contractual rights over external partners, the system risks straining under pressure.
3. Strategic Necessity of Preemptive Contractual Oversight
Modern vendor management requires robust "Right-to-Audit" clauses, mandatory disclosure of executive financial interests, and zero-tolerance hospitality guidelines embedded into every commercial agreement prior to execution.
V. Discussion Questions for Class or Personal Analysis
1. Investigative Strategy: If you were Chief Compliance Officer (CCO) facing an uncooperative third-party vendor during a critical internal investigation, what alternative tools or contractual leverage would you employ to verify executive compliance?
2. Contractual Design: How should enterprise procurement and legal teams draft third-party vendor contracts to ensure total transparency, audit access, and immediate termination rights in the event of uncooperative behavior during an ethics inquiry?
3. Culture & Leadership: How can executive leadership restore organizational stability and focus when an internal investigation ends inconclusive, yet leaves behind lingering tension and operational distraction and a sense of distrust?
Bonus Question: Should they?
Discuss amongst yourselves: What Do You Think?
Email us at
globalhcanalytics@gmail.com or visit this website:
Or Click Here: https://www.amazon.com/Blood-Money-Celgenes-Collapse-Acquisition/dp/B0HN6429P9/ref=tmm_pap_swatch_0
For a paperback or Amazon Kindle (fancy PDF :D) Copy!
Artificial Intelligence
This is a brand new website.
HCD Expertise
It is under construction.
Strategic Consulting
Check back soon.
About Jeff Conroy
We are a boutique consulting firm.
We offer Expertise in Healthcare Analytics of all types - primarily focused on the life sciences industry.
This website is constantly under construction.
AKA The Art of Persistent Positive Self Improvement!
Check back soon! We hope to Hire More People. =)
~Jeff - or just follow me on LinkedIn, Here:
